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Abstract
The objective of this project was to produce novel dtug-
tronOClonal antibody irrm.moconjugates for site specific drug
delivery. 'I1J.e m:xlel in these studies consisted of a target.
the turror associated carcinoembryonic antigen (CFA) expressed
by a wide raD3e of hlunan solid turrors. and conjugates of
doxorubicin (Adriamycinl!l) (Dox) , potent antibiotic
chemotherapeutic drug, covalently linked to a monoclonal anti-
CEA antibody by different heterobifunctional cross-linking
reagents.
The structure of cross-linking reagents were fully
characterized by chemical spectroscopy, infrared (IR), lH and
IlC nuclear rrasnetic resonance (Nv1R), and nass spectra (MS).
The spacer-Dox derivatives were also characterized by 'H Nv1R
before coupling to thiol groups of thiolated monoclonal anti-
cr.A antil:xxiy. 'nle inmunoreactivity of irmunoconjugates was
evaluated by enzyrre linked innunosorbent assays (ELISAs) which
showed that all ilTl'l'lJI'lOCOnjugates retained specific bindi03 to
CEA. The efficacy of irmrunoconjiJgates was determined in MTT
()-4, S-dirnethylthiazol-2, S-diphenyltetrazoli.ll1l brOOlide) cell
survival assays. The Dox 3' -N-amide linked irmrunoconjugates
are not very active in vitro with CEA. expressing cell 1toes.
However, the Dox C-13 hydrazone linked iTTlllUCloconjugates are
active in vitro.
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CHAPTER I INI'RODUcrION
I 1.0 CURRENT RESEARCH IN DELIVERY OF ANTICAN~ DRUGS
A cancer represents a population of cells within the host
body escaping from normal control mechanisms which will
continue to grow until the death of the host, unless
appropriate treatment is applied. The turoor may be controlled
by surgical rem::>val, radiation killing or chemical treatment.
Surgery and radiotherapy are only successful in localized
cancers while chemotherapy is a major therapeutic approach for
the treatment of both localized and metastasized cancers.
Cancer chemotherapy has had rerrerkable success for certain
tumors, e.g., childhood leukemia, choriocarciru:xna, and
testicula~- carcinoma (DeVita & Hellman, 1982), but it has been
relatively ineffective for many of the fOClre carrmon tUm::>rs,
e. g., lung cancer and colon cancer. All cytotoxic drugs used
in cancer therapy share two properties: an ability to inhibit
the process of cell division and an inability to distinguish·
between normal and malignant cells. The effectiveness against
these tUll'Ors rrey be increased if chugs are more specific end
selective to turror cells. 'IW<:l approaches have been used to
produce antitumor agents for improving therapy such as design
of analogues by chemical modification of the parent drug
(Cassady &. Douros, 1980) and genetic engineering of antibiotic
producing microorganisms (Hutchinson et aI, 1989). However,
only a few dJ:ugs scanned from nany hundreds have reached
clinical usefulness because of nonspecific toxicity and poor
therapeutic index. In recent cancer chemotherapy research,
significant efforts have been directed towards the improvement
of anticancer drug delivery. These include pharrnacokinetic
and pharmacodynamic considerations, therapeutic implications
and mechanisms of drug resistance. These approaches appear to
be a challenging field in cancer research.
The pharmacokinetic aspect is the study of the rate of
change of drug concentration in vivo related to drug dose,
frequency, and route of administration (Levin, 1986). The
pharmacodynamic aspect is the study of the time relationship
of pharmacological response elicited by drugs or r-elationship
of drug concentration at a receptor site to biological
response (Powis, 1985). Both aspects can be applied to design
the dosage of anticancer drugs for achieving the desired and
optiwal therapeutic effects.
'!he development of multiple drug resistance (MDR) in
tumors has become challenging problem in cancer
chell'Otherapy. The studies of MDR focus on the mechanisms at
the level of membranes, cytoplasms, and DNA repair and gene
amplification (Hayes & Wolf, 1990: Burt, Fojo & nJ.orgeirsson,
1990; Nielsen & Skovsgaard, 1992). The problems of MDR can be
overcome by several approaches: 1) drug rrodificati.on such as
increasing lipophilicity (Meyer, Stone & Ull1T'aIl, 1979); 2)
utilization of IOOnoclonal antibodies (MAbs) or monoclonal
antilxxiy-drug conjugate against unique glycoproteins of
resistant turror cells (Pearson et aI, 1991; ohkawa et aI,
1992); 3) using calcium channel blockers (Helson, 1984; Cano-
Gauci & Riordan, 1987); and 4) decreasing the cytoplasmic
level of glutathione (Ozols et aI, 1987).
The general approaches for delivery of anticancer drugs
in achieving therapeutic improvement are: 1) liposome delivery
systems (Weinstein & Leserman, 1984); 2) microparticulate drug
delivery systems (Kerr, 1987); 3) macromolecular drug
conjugate systems (Maeda & Matsurmrra, 1989; Seymour, 1992); 4)
polymeric controlled-release systems (Laurencin & Langer,
1987; Yokoyama et aI, 1992); 5) blood-perfluorochemical
exchanges (Hiraga et aI, 1987); 6} m:moclonal antil:xx:ly-
mediated targeting (Ford & Casson, 1986; pietersz & Mckenzie,
1992); 7) implantable pumps and reservoirs for regional
perfusion (Freeman & Mayhew, 1986); and 8) prodrugs for site-
specific delivery by targeted enzymes (Senter et aI, 1993).
The approach which represents one of the more significant
developments is the use of monoclonal antil:xxiies (MAbs) to
concentrate drugs to a tlJl'TOr. During the past decade, there
has been a rapid growth of drug targeting using MAbs as a
result of the consolidation of different scientific
disciplines, cell biology, recombinant technology and
chemistry. Within the area of cell biology, hybridoma
technology allows unlimi ted production of MAb. After
irrm..mization of a rrouse with human tumor tissue containing
specific turror associated antigen, the irrrnune system of the
mouse pro~esses the antigen and begins to IT'axe antibodies.
The 8 cells obtained from excising the spleen c,re fused with
malignant myeloma cells and the fused hybridama. cells are
selected from specific medium such as HAT (hypoxanthine
/aminopterin/thymidine). The MAbs derived from the hybridoma
cells are screened against malignant and normal tissue. The
improvement of screening and testi.ng for the innnmoreactivity
of derived MAbs has accelerated the growth of the drug--
targeting discipline. Recombinant DNA technology has allowed
the construction of chimeric rronoclonal antibodies for drug
conjugation which reduce their irrmunogenicity in humans
(Beidler et at, 1988; Fell et al, 1989). Olemistry has
accelerated the evolution of the drug-targeting. The
importance of chemistry is the design and synthesis of
bioconjugates in which the linkages of drugs are compatible to
MAbs. 'These three di.sciplines create a new dimension that
facilitates the advance with rocmoclonal antibody drug
targeting in the treatment of human cancer.
I 2.0 ANrlBODY MEDIATED TARGE'l'IID (AMT)
I 2.1 Concepts and carponenta in Targeted Chemotherapy
The major obstacle in cancer chemotherapy is the lack of
selectivity of therapeutic agents for the malignant cells and
the toxic side effects to normal cells in therapeutic dosage
(Ford & casson, 1986). Targeted chemotherapy offers an
approach to increase drug delivery to the turrer site. This
approach was originated from proposals of Paul Ehrlich in the
early years of this century. He postulated 'magic bullets'
for ligand substrates in drug targeting (Ehrlich, 1906). The
basic conc,-;pt is to link the therapeutic agents to a s!te-
specific carrier directed against tumor cells. Thus, the
components of targeted cheootherapy consists of 1) target, 2}
carrier, and 3) toxic agent.
II 2.2 Targets
II 2.2 (a) Antigen Specificity
The explicit difference between tumor cells and normal
cells is a prerequisite of selectivity for drug targeting.
The search for turror specificity was begun by Enrlich in the
early 1900' s. The claims for the "turror specific markers"
remained controversial until the derronstrations of turror
specific antigens (TSAs) induced by chemical carcinogens in
syngeneic mice were established (Klein el at, 1960; Schreiber
et aI, 1988). 'l11e characterization of oncogenic products
(Harris, 1990) strongly suggests the existent of distinct
molecular differences between tunDr and normal cells.
However, the presence of TSAs in hunan tumors rem3ins lmproven
with the exception of the idiot~tpe narker on certain 8 and T
cell lymphomas and leukemias (Old, 1981; Stevenson, George &
Glennie, 1990).
The best potential targets for site-specific drug
delivery are the tumor associated antigens (TAAs) available in
greater canten>;: on a tumor cell surface than on normal cells.
An ideal ttullOr marker should possess these several
characteristics 1) it should be produced by the tumor cells
and be easily detectable in body fluids; 2) it should not be
present in healtl1)' cells or benign diseases; 3) it should be
present in concentration high enough for screening and
detecting early cancer levels; 4) it should directly reflect
the bulk of turror in terms of the quantity of marker; 5) it
should be detectable without clinical evidence of a turror; and
6) it should correlate with the efficacy of anti-cancer
therapy (Bates & Longo, 1987). However, no marker meets all
of the above criteria.
A wide range of tlUTlOr associated antigens were identified
and evaluated as tumor markers in cancer diagnosis and
managel"(l:!ot (Table 1) (Bates & Longo, 1987). Many MAbs have
been made to antigens strongly expressed by human tumors.
Most of these antigens are ancofetal antigens. In solid
turrors, three TAAs, carcinoembryonic antigen (CEA.) ,
alphafetoprotein (AFP) and human chorionic gonadotrophin
(HCG) , are well characterized. Among the alx:lVe TAAs, CEA is
the most well-studied tUll'Or marker. Extensive research has
been in progress to dissect CEA at both the cellular and
molecular levels (Shively & Beatty, 1985).
Table 1 : Classification of Turror Markers
Oncofet~l antigens
Ectopic horm:mes
Placental proteins
Enzyme
carcinoembryonic antigen
Alphafetoprotein
Adrenocorticotropic horTOCme
Antidiuretic horroone
Parathormone and Calcitonin
Human chorionic gonadotrophin
~= r;~~~~~ ~6~t~~line
phosphatase)
Prostatic acid phosphatase
Lactic dehydrogenase
Adapted from Bates & Longo, 1987
I 2.2 (b) Choice of Target Antigen
Vlliile considering an antigen as a target for therapy,
both the degree of antigen specificity and the number of
antigenic rrolecules per tumor cell are important. The
importance of antigen specificity is obvious because it allows
the conjugates to anchor on the antigen-positive tumor cells
selectively and accurately while sparing antigen-negative
nonnal cells. However, an entire targeting system would be
useless if the expression of the target antigen at the cell
surface \<O.Ild not permit the binding of the number of ~.
antibody conjugate rrolecules needed to achieve the therapeutic
response.
r-bst drugs rrust enter tumor cells to exert an effect;
thus, the degree to which a drug-antibody conjugate is taken
up by the cells is also important. The uptake is generally
facilitated by endocytosis and the degree of endocytosis may
vary between different antigens. Conjugates that ar.e
internalized may be more effective for delivery of drugs
intracellularly.
I 2.2 (c) Characteristics of Targets
n.unor cell heterogeneity is a problem in roth diagnosis
and treatment of cancer, and this heterogeneity shows a large
variety of characteristics (Foulds, 1954; H:lrt 6< Fidlp.:r, 19B1;
Fidler & Poste, 1985; Schnipper, 1986). ntese include
sensitivity to chemotherapeutic drugs and expression of turror
antigens (Yeh, HellstrOm & HellstrOm, 1981; Albino et al,
19B1) . The therapeutic problem of drug sensitivity can be
approached by MAbs conjugated \r/ith multiple drugs or a
"cocktail II of conjugates (Oldham, 1991). The antigenic.:
modulation, rmJtational loss of TM and shedding of antigens
into the Ixx:ly fluids impede the efficacy of using antilxxly for
10
therapy. The phenomenon of antigenic m:xiulation in which
antibody-coated cells redistribute and then clear the
antibody-antigen c.:omplexes provides an effective way of escape
from inmune attack (Gordon & Stevenson, 1981, Gordon et aI,
1984) . The mutational loss of surface antigens may lead to
escape from attack by antibodies or conjugates (Meeker et a!,
1985; Glennie ec aI, 1987). The shedding of antigens into the
body fluids may lead to fo:rmation of antibody/antigen
complexes which are rapidly removed by the reticuloendothelial
system (RES).
I 2.3 Carriers
Site specific delivery of cherootherapeutic agents is now
receiving rrore attention in effective cancer chemotherapy.
The aim is to develop the carriers that will show a high
degree of selectivity in bringing the therapeutic agents into
the target sites. An ideal carrier should possess the
following properties: 1) the carrier delivers the toxic agent
selectively to the target sites; 2) the linkage between the
carrier and the toxic agents retains the activities of both
agents; and 3) the carrier has reasonable stability for
delivery purpose (Ford & casson, 1986).
:I 2.3 (a) Types of Carriers
A wide range of different drug carrier systems, polymers,
11
macrorrolecules, nanoparticles, liposomes and monoclonal
a.,tibodies are tmder investigation for the a1:x:Ive properties.
The most outstanding carriers for targeted drug delivery are
antibodies and liposomes.
The use of liposomes as a carrier system improves the
therapeutic efficacy of a wide range of drugs (Weinsteain &
Leseman, 1984), especially for lipophilic antiturror drugs.
Because of their particulate nature, liposome entrapped agents
afpear to be promising for the treatment of tumors of the
reticuloendothelial system (RES) by intravenous administration
and turrers of body cavit:'es by intracavitary administration
(Perez-Soler, 1989). 1he liposomal stability and clearance
are controlled by the composition of the vesicles themselves
(Allen & Qlonn, 1987). Thus, liposome composition can
determine the amount of drugs delivered to tumors and the
uptake of liposanes by tumors (Gabizon & Papahadjopoulos,
1988) . However, the problems of using liposomes are
nonspecific uptake by the phagocytic cells in the RES, pooI.'
penneabilicy out of the blood stream, degradation, toxicity
and antigenecity (Gregoriadis, 1990). Inm.moliposomes using
an antibody as a targeting ligand and a lipid vesicle as a
carrier for anticancer agents enhance the site-specific
delivery to target site (Wright & Huang, 1989).
The specificity and monoclonality of MAbs offer the best
potential carrier system to achieve major advances in targeted
12
drug delivery.
I 2.3 (b) Antibodies as Carriers
The special i1lTlUlnOlog"ical properties that enable selected
antil:xxiies (Abs) to localize and accumulate in tumor sites
favor the application of Wills as drug-targeting agents. The
concept of using MAbs as carriers of therapeutic agents is
sirrple, straightforward and attractive. However, the
investigation of antibody mediated targeting (AMT) did not
gain attention until the early 19708. The exploration was
hindered by the following impediments: 1) apprehension
regarding administration of large quantities of foreign Aba to
patients; 2) development of an imnune resfX)nse when these Aba
were repeatedly administered; 3) heterogeneity of Aba; 4)
poorly defined targets; and 5) lack of relevant preclinical
models for in vivo testing (Ford & casson, 1986). Some of
these obstacles have been partially or completely reduced.
The discovery of MAbs in 1975 (KOhler & Milstein, 1.975)
led to the homogeneous unlimited supply of monoclonal
antibodies with defined specificities and also opened the
avenue for antiOOdy-mediated targeting (AMI'). For the
production of MAbs, a lOO"..tse is usually irrrmmized with the
antigen of interest, e.g., human cancer tissue. The mouse is
the system of choice because hybridoma technology was
developed within the context of toc>Use genetics (KOhler, 1986).
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By these techniques, Abs harvested represent a nllInber of
different classes and isotypes. Moreover, IgG antibodies are
preferable to IgM because they ll\3.y concentrate better. at the
target due to their sfl'laller size. 'Ihere are two ways to
obtain an IgG-producing hybridcxna when starting with IgM-
making hybridona: 1) perform "class-switching" (Tharrrrana &
Scharff, 1983), and 2) obtain a new hybridorra with the
specific antil:xxly isotype when the antigen is already defimd
(Brown et al, 1980; Brodin et aI, 1985).
I 2.4 Monoclonal Antibodies for Cancer Diagnosis and Treatment
MAbs reacting with hunan TAAs have been used. for tumor
detection and therapy. The uses of MAbs in the diagnosis of
cancer are as follows: 1) irrrrn..mohistopathological diagnosis;
2) serum probes for tumor markers; and 3) radioil1Tl1UI1odetection
(RAID) (Teh et al, 1985).
MAbs can be used either alone or as carriers of toxic
agents in cancer treatment (Houghton & Scheinberg, 1986; Byers
& Baldwin, 1988; Dillman, 1989; Ford et aI, 1990; PieLersz &
Mckenzie, 1992). The therapeutic application of MAbs include:
1) mediate destruction of target tun"Or cells by cootplement
(complement-mediated cytotoxicity); 2) mediate killing of
target tUlTOr cells by irrrm.me effector cells (antibody-
dependent cellular cytotoxicity); 3) direct biological effects
on target cells, eg, block cell proliferation; and 4) exert
,.
cytotoxic/cytostatic effect when conjugated to anticancer
agents (Houghton & Scheinberg, 1986). The novel approach
involving the anti-idiotypic therapy for leukemias and
lymphomas (Stevenson, George & Glennie, 1990) is also Wlder
consideration. Aba alone are generally not very efficient in
the treatment of cancer, but act as carriers when conjugated
to toxic agents, giving an appropriate targeting system.
I 2.5 Immunoconjugates for Cancer Diagnosis and Treatment
MAbs which recognize TAAs offer the greatest potential as
carriers for site specific targeting. The toxic agents
conjugated to MAbs include radioisotopes, toxins, enzymes and
anti-cancer drugs (Pietersz & Mckenzie, 1992}.
I 2.5 (a) Radioimnunoconjugates (RCs)
Radioirrrnunoconjugates (RCs) , antibodies labelled with
radionuclides, in addition to diagnosis and therapy in cancer,
have potential in quantifying and studying the
pharmacokinetics of MAbs. However, the problems of low
localization of radioactivity in tumor, high localization of
radioactivity in nontarget organs such as liver, and human
antirrouse antibody l-esponse (HAMA) limit the usefulness of
Res. Thus, recent work has .focused on methods for the
preparation of Res to increase their efficacy. Different
linking or chelating ageuts for the attachment of
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radioisotopes to MAbs or antiJ.xxiy fragments have been prepared
and the feasibility and effectiveness of these conjugates have
been widely explored (Garg, Garg & Zalutsky, 1991; Arane et
ali 1991i Hadley et al, 1991; Linder et al, 1991bi Griffiths
et aI, 1992).
The use of radioiodinated antibodies for tUlllOl"
localization was pioneered by Pressman and Goldenberg
(Pressrrann & Keighley, 1948; Goldenberg et al, 1978). 111e
methods and reagents for labelling MAbs with radiohal03ens
have been recently reviewed (Wilbur, 1992). The clinical
radioinmunodetection (RAID) trials has been recently
surrrnarised and reviewed by Larson (Larson, 1990 & 1991). The
radioiodinated antibodies (lUll have been widely used for the
diasnosis of a range of tu....rors; however, llil is not an ideal
radiolabel due to high energy p-emission. The high photon
energy results in poor detection efficiency, reduced
sensitivity and resolution (Bradwell et aI, 1985), Other.
radionuclides, indium-HI (111In) (Brandt & Johnson, 1992;
SUbramanian et aI, 1992) and teclmetium-99m e'-"Tc) (Linder el:
aI, 1991a), have ideal half lives and photon energies, but
they are expensive.
The use of Res as therapeutic agents offers an attractive
approach in cancer therapy, radioil11Tll.ll1otherapy (RAIT) , The
use of radioisotopes in RAIT has a number of advantages: 1)
the small size of isotopes does not greatly alter the
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conformation of MAbi :2) the bombardment property of isotopes
to the surrounding cells provides effective treatment with
heterogeneous tumors in which the tumor cells are killed
without the binding of RCs; 3) the conjugates acting over long
distance affect the tumor cells in the interior of the tUfOClr.
'These advantages encourage the clinical studies with RCs,
especially ilIr (Moseleyet aI, 1990; Goldenberg et aI, 1991;
camera et aI, 1991,' Meredith et aI, 1992). Other isotopes,
palladium-lOg (Fawwaz et aI, 1984) I bismuth-212 (Kozak et aI,
1986) I yttrium-gO (Vaughan, Keeling & Yankuba, 198');
Vriesendorp et aI, 1991; Rosenblum et aI, 1991) and astatine-
211 (Harrison & Royle, 1984; Brown, J986l, are under
investigation. The use of interleukin (IL-I) following
radioirrmunotherapy has been shown to increase survival of mice
(Blumenthal et aI, 1988) and may be used in t.he future.
Another possibility for RAIT involves the use of boron-10 (lOB)
in boron neutron capture therapy (Barth, Soloway & Fairchild,
1990; Varadarajan & Hawthorne, 1991).
I 2.5 (b) Immunotoxins (ITs)
Toxins are usually of plant or animal origin and more
potent than cherrotherapeutic drugs, low concentrations of
toxins are sufficient for cell killing (Yamaizumi et al, 1978;
Biklid, Clsnes & Pihl, 1980). Most toxins are peptides that
inhibit the elongation step of protein synthesis. Conjugation
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of toxins to MAb, ilTll1JIlOtoxins (ITs), represents a potential
anticancer agent and a new approach to cancer therapy (Lord,
Spooner & Roberts, 1989). Thus, several toxins, ricin, abrin,
gelonin, pseudomonas exotoxin A and diphtheria toxin, have
been conjugated to Wills for evaluation. The efficacy of ITs
in vitro and in vivo have been reviewed (Vitetta et aI, 1987;
Byers & Baldwin, 1988; Hertler & Frankel, 1989). The
construction of ITs requires the relOOval of the cell-binding
rroiety (8-chain) by chemical cleavage or modification and then
the coupling of toxic moiety (A-chain) to MAb via a reducible
disulfide bond with the use of a heterobifunctional cross-
linker such as N-succinimidyl 3- (2-pyridyldithiol propionate
(SPDP). From genetic engineering techniques, the recombinant
toxins have been cloned with ligands to fOl'm the chimeric
toxins for receptor-targeted therapy (Murphy et a1, 19B6;
Kreitman et aI, 1992a). By recombinant technology, It is
possible to design chimeric toxins with two recognition
donains by placing tWCl ligands into different locations of the
same toxin to increase efficacy (Kreitman et aI, 1992b).
Another novel approach is the construction of ITs with a
photocleavable linker and their cytotoxicity can be controlled
by an external signal such as W light at the desired site and
at the desired time (Goldmacher et aI, 1992).
Clinical trials have been performed using ITs for the
treatment of chronic lymphocytic leukemia (CLL) (Hertler et
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al, 1989), cutaneous T-cell lymphc:xn<i (LeMaistre et aI, 1991),
8 cell leukemia (BCL) (Vitetta et al. 1991; Grossbard et al,
1992), metastatic malignant melanoma (Spitler et al, 1987),
metastatic breast carcinoma (Gould et aI, 1989; Weiner et aI,
1989) and graft-versus-host disease (GVHD) (Kentan et aI,
1988) .
The use of ITs in viva may be hindered by several
problems. A number of avenues have been explored to irrprove
their etficacy. The disulfide bond linkage used to prepare
ITs is susceptible to reduction in vivo and the arrount of
toxin delivered to target cells will be greatly reduced.
Th.us, the efficiency is low. New cross-linking agents with a
hindered disulfide bond that is more resistant to reduction
have been developed ('!harpe et aI, 1987; Greenfield, Bloch &
M:lreland, 1990; cumber et aI, 1992). The failure of ITs to
permeate solid turrors limits their potential in therapy. This
problem may be solved by reducing the size of IT with the use
of fragments of antilxxly (Fab') (Vitetta et al, 1991). The
antibody and toxic moieties of IT are antigenic and provoke
irrmune responses, HAMA and HAM (human anti-ricin antilxxlies).
The problem of HARA may be improved by using a range of
different toxin 11'01ecules. The use of a chimeric antibody can
reduce the ill1llUnogenicity of ITs (Siegall et aI, 1992). Much
future 'NOrk will be done to irrprove the efficacy of ITs for
targeted. therapy.
19
I 2.5 (cl Antibody-Enzyme I:lmtunoconjugates (Era)
A recent novel idea is a site specific antibody directed
enzyme prodrug therapy (ADEPT) (Bagshawe, 1993). Antibody-
enzyme conjugates (EIa) can be targeted to the turror site in
which nontoxic drug precursors (prodl:ugsl are activated to
toxic drugs by targeted enzymes (Bagshawe, 1989; Senter, 1990;
Senter et aI, 1993). A number of agents have been used in
vitro and in vivo studies (Wallace & Senter, 1991; Jungheim,
Shepherd & Meyer, 1992; Svensson et a1, 1992; Wang et a1,
1992; Vrudhula et aI, 1993). The clinical trial from Bagshawe
et a1. shows the therapeutic effects from this idea, but the
problems are HAMA. as well as an anti-enzyme antibody (Bagshawe
et aI, 1991). Recently, a fusion protein consisting of the
humanized Ab and the hurran enzyme may solve the aoove problem
and allow ADEE"!' in vivo (Bosslet et aI, 1992).
I 2.5 (d) Antibody-Drug Im:nunoconjugates (ICs)
Anti-neoplastic dnlgs as toxic agents for coupling to
MAbs is now attracting more interest as the drugs are widely
used for therapy and have defined mechanisms of action and
ph.a.rm3.cokinetic properties. It would be rational to perform
the conjugate Phase I trials with dxugs whose antitumor
activity and toxicity are known. 'l'hen, the toxicity from the
conjugate can be compared with the known toxici.ty of an equal
dosage of the nonconjugated dnlg. Subsequent Phase II trials
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can then compare the therapeutic effect of Ie with :.m equal
toxic dose of the free drug. The cytotoxic drugs that have
been used for conjugation include methotrexate, vindesine,
neocarzinostatin, cis-platinum, chlorambucil, 5-fluorouridine,
melphalan, daunomycin and adriamycin.
The first report of targeted chemotherapy came out in
1958; MatM demonstrated the prolongation of survival of mice
with methotrexate (MIX) using an antiserum against the mouse
leukemid LI2l0 raised in hamsters (Mathe er. aI, 1958). The
result was due to the synergistic effect of Ab and the drug in
noncovalent linkage. For a targeted approach, chugs should be
covalently linked to the antilxxiies (Newman et aI, 1977). A
lot of preclinical and clinical studies have been reported
with different lCs. Clinical trials using human studies were
pioneered by Ghase' s group, using chlorambucil (CBL) bound to
xenogenic antimelanoma globulin (Ghose et al, 1975). One
recent refXJrt establishes the usefulness of lCs in clinical
trials and describes the follow-up results in a large number
of colorectal cancer patients treated with chimeric Fab MAb
A7-neocarzinostatin (NCS) conjugates (Takahashi et aI, 1993).
Preclinical studies of vindesine (VDS) linked to MAbs have
derocmstrated efficacy, both in vitro and in vivo, of AMr which
correlated wlth target antigen expression (Rowland et aI,
1985i Ford et aI, 1987b). Other preclinical studies using r·t.\b
and derivatives of the vinca alkaloid, desacetylvinblastine
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hydrazide, have also demonstrated significant increases in
survival times of the animals (Apelgren et at. 1990 & 1993;
Starling et aI, 1992) . Other studies including
anthracyclines, Dox (Dillman et aI, 1986; Sinkule, Rosen &.
Radosevich, 1991) and daunorubicin (Dau) (Dillrran. et aI, 1988;
Stastry & Das, 1993) and MIX (Kralovec et aI, 1989) also
showed promising results.
The major problem for the prodUl.. :tion of ICs is the
retention of the activity of ooth the dnJ.g and the antibody.
Most conventional conjugation procedur.es such
glutaraldehyde and carbodiimide result in loss of drug and/or
antilxxlyactivity. When dnJ.gs are conjugated to antibodies,
certain chemical groups of the drug can not he modified due to
their importance in cytotoxicity to t.arget cells.. Thus, the
structure-activity relationship of the dnlgs should be
enphasized.. Most drugs are hydrophobic and change the
solubility of antil:xxly after conjugation, leading to
aggregation. Moreover, the linkage of drug to antibody should
be stable in the plasma so that the drug is not released
prematurely.. The synthesis of these conjugate requires
extensive chemical manipulations. The cytotoxic effects of
the ronjugates may depend on drug release t1r internalization.
Thus, more studies will be directed toward the chemical
linkage in the preparation of ICs.
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I 3.0 RATIONALE FOR THE USE OF A CEA MJDEL
Before the evaluation of the role of rcs in
chemoirrrrunotargeting, it was crucial to choose the appropriate
target to study. A target should be present on the major
solid turrors for which improvement in chemotherapy was
urgently needed. The MAbs to the target should be available
and :::iuitable for targeting. The target could be easily
assay~ in the laboratory and the st::ructure well elucidated.
CEA is the most widely studied and utilized human tumor marker
(Shively & Beatty, 1985) and, in our opinion, is the roost
suitable target for detailed studies.
I 3.1 Molecular Structure, Evolution and Functional
Significance
CEA was first described by Gold and Freedman as a high
molecular weight glycoprotein {-lSO.OOO} associated. with
colonic tumors and fetal <.:010n (Gold & Freedrran, 1965). The
antigenic structure of eRA has been well characterized by
using over 52 MAbs (Harrrnarstrom et aI, 1989). The CEA gene
family, molecular structure, evolution and functional
significance have been extensively reviewed (Rogers, 1983;
Shively & Beatty, 1985; 'I'horrpson & Zirrrnemann, 1988; Thompson,
Gnmert & Zirrmerrrann, 1991).
11le function of CEA as an intracellular adhesion rrolecule
was suggested by Benchimol's group (Benchimol et aI, 1989).
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Thus. CEA has joined the irtm.lIlO9'lobJUn (Ig) superfamily,
involving the basic cell surface recognition events (Williams,
1987) .
I 3.2 Clinical Relevance
CEA is the best known TAA which often e:dsts in elevated
levels in cancer patients and is associated with lTOst of the
conm::m solid t\.1lOOrs that have the highest mortality: :.65% of
colorectal, ::.50% of lung, ;:.60% of pancreas, ,30% of 0Vaty and
breast cancers (Bates & Longo, 1987). CEA was not only
identified in the circulation of cancer patients, but also in
patients with benign disease, healthy controls and even in
normal tissues. However, (FA is still a uneful marker for
cancer and its level is a valuable parameter in assessing
cancer therapy.
I 3.3 CEA as a Model for Antibody Mediated Targeting
CEA. is established as a prc:mi.sing target in both antil:xx:ly
mediated diagnosis and treatment. The potential of polyclonal
antibodies (pabl anti-CEA-VDS Ie was delTOnstrated with
retention of chug and Ab activities as well as Ab specificity
(Johnson et aI, 1981; Rowland et aI, 1982). Then, an 1"1
labelled anti-CEA, conjugate was used to localize the turror in
patients with advanced rretastatic adenocarcinomas (Ford et a1.
1983). With the inproveJrel1t of RAID technique, lUI, "-r'c and
2.
11110 labelled MAb or Fabs have been used to detect CEA
expressing turrors (Beatty et aI, 1986; Goldenberg et aI,
1990) .
One of the anti-CEA ("1Abs, 11-285-14, has been well
characterized inmunocytochemically (Hockey et aI, 1984; Ford,
Gallant & Ali, 1985), and confirmed to be reactive only with
CEA and non-reactive with normal cross-reacting antigens INCA)
(Price, 1988). The efficacy and specificity of 11-28S-14-VDS
lCs have been shown in vi tro and correlated with CEA density
in different cancer cell lines (Ford et aI, 1987b). These
conjugates have also dem:mstrated their efficacy in vivo with
xenografts in a nude lOClUse model (Casson et aI, 1987).
Further studies of 11-285-14 in AM'!' with 11-285-14-Dox
conjugates have indicated specificity for the CEA target in
vitro (Richardson et aI, 1989).
The rationale for CEA m:xiel:
1) 'The comron solid tUlOClrs such as colonic, lung, stomach
and breast cancers, show high expI·ession of CEA and these
are the turrors in which improved chemotherapy is
required.
2) CEA is the rrost well studied, characterized and
elucidated TM.
3) The anti-CEJ:.. MAb, 11-285-14, is reactive with CEA
expressing cell lines and nonreactive t.o NCA (Price,
1988) .
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4) 11-285-14 has been demonstrated to be bound and
internalized by CEA expressing cells in vitro {Tsaltas,
Fcrd & Gallant, 1992).
5) The CEA rocx:lel in AMI' has been developed from 11-285-14-
VDS in vitro and in vivo as well as 11-285-14-Dox in
vitro (Ford et aI, 1987b; Richardson et aI, 1989)
I 4. a RATIONALE FOR THE USE OF OOXORUBICIN
There is a vast selection of cancer drugs in clinical use
and the anthracyclines have the widest spectrum of antitulTIex
activity. Thus, they have aroused considerable interest for
cancer treatment. This class of compounds is exemplified by
doxorubicin (Dox), an antineoplastic antibiotic, isolated horn
a culture of Streptonwces~ var. ~ and
introduced into clinical use in 1976. Dox (Adriamycid") has
the widest range of antiturror activity, ranging from leukemias
to a broad spectnlm of solid tUll'Ors such as breast, lung,
stomach and colonic cancers (Blum & Carter, 1974) and may be
the most utilized antiturror drug worldwide (Weiss et al,
19861.
I 4.1 Structure and Mechanism of Action
The structural elucidation of Dox shows a characteristic
four-ring structure, anthraquinone clu:oroophore, linked to
daunosamine via a glycosidic bond and the presence of a ketone
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and a hydroxyl at the 13 and 14 position respectively (Figure
1) (Arcamone, Franceschi & Penco, 1969). Dox is chemically
named (98,75) -7- [(3' -amlno-2' ,3' ,6' -trideoxy-a:-L-lyxo-
hexopyranosylloxy] -7.8, 9,10-tetrahydro-6, 8, 11~trihydroxy-9­
fhydroxyacetyl) -4-methoxy-S, 12-naphthacenedione.
Dex exhibits three principal toxic effects on cells. The
first is the interference with DNA metaOOlism (Zunion,
Gambetta & 01 Marco, 1975; Liu , 1989). The second is
interference with electron transport and cellular respiration
(Marcillat, Zhang & Davies, 1989; Demant, 1991). The last one
is with lipid peroxidation and disruption of the cellular
membrane (Myers et aI, 1977; Glarmi et aI, 1988) .. thus, Dex
may be toxic to cells even without entering the cells (Tritton
& Yee, 1982).
I 4.2 Potential in Targeting
Although Dox is very useful in chemotherapy, its efficacy
is impeded by toxicities, including myelosuppression,
mucositis and alopecia. The greatest concern is the unique
cumulative cardiac injury which is the major obstacle to the
use of Dox in cancer treatment.
The rationale for producing MAb-Dox irrmunoconjugate
includes:
1) The potential of increadng selectivity to cancer cells
and decreasing toxicity to normal cells, thereby
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Figure 1. Chemical Structure of Doxorubicin
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increasing therapeutic index.
2) Other rrore potent derivatives of Dox such as
cyanorrorpholinodoxorubicin, 2 to 1000 times TOClre potent
than Dox (Beckman et aI, 1988), are not being used in
cancer treatment because of their non-specific
toxicities, but can be conjugated to MAbs for targeting
and may retain anti-tt1lOCJr activity with lower non-
specific toxicity.
I 5.0 METHODS OF CONJUGATION
Bioconjugation chemistry is a descriptive term for the:
joining of two different rrolecular functions by chemical or
biological means (Meares, 1990). The science and goal of
conjugation involve extensive chemical experimentation and
product characterization prior to performance of the
biological experiments. The multiple steps of the chemical
process in preparing and characterizing the bioconjugates
provides reliable results and methodology even without
encouraging biological results.
The process of joining two molecular components by a
covalent l::xmd can be achieved through the use of cross-linking
reagents. The corrponents may be proteins, peptides, dnlgS or
nucleic acids. The reagents and methods for protein
nooification have been reviewed (Means & Feeney, 1990;
Lw1.dblad, 1991). The methodology of Ab rrodification and
"
chemical linkage of cytotoxic drugs to MAbs will be discussed
in sections 5.1 and 5.2 respectively.
I 5.1 Chemical Modification of Antibodies for Conjugation
Methods for the chemical rrodification of Ab continue to
expand and develop. '!he tremendous growth of chemical methods
and researchs involve not only fundamental biochemical
structure and function, but also pharnacological or medical
diagnostic applications.
Conjugation of Abs to other components such as enzymes,
toxins, radiolabels or cytotoxic agents depend on the
reactivities of the amino acid side chains and the
specificities of cross-linkers used. There are twenty amino
acids with side chains of different chemical reactivity, but
only a few of the amino acid side chains are reactive for
modification (Figure 2) (Wong, 1991). The reactivity of Abs
that can be chemically modif:..ed are also determined by their
amino acid cOOlIX'sitian and the sequence location of the
individual amino acids. Lysine residues are usually the Host
ab.mdant amino acids in proteins and they can he found on the
surface of antibody rrolecules. Thus, the nucleophilic € -amino
group of lysine residue will be the corrmon target for chemical
roodification.
Special reactive groups can be intrcx:1uced into Abs by
chemical rrodification of the existing flUlctional groups by: 1)
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using cross-linking reagents; 2) creating aldehyde groups by
carbohydrate oxidation with sodium periodatei and 3) reduction
of disulfide ronds by dithiothreitol to expose free thiol
groups. TIle addition of new fW1ctionalities se:rve many
purposes including: 1) the incorporation of spacer arms from
the protein surface can reduce the steric hindrance caused by
other amino acid side chain::; and decrease the effect of local
environment; 2) inactive units can be activated to fllllctional
groups for further reactioni 3) the conversion of one
functional group into another can either change its
specificity or reactivity. Thiolation of Abs plays an
important role in conjugation,· the thiol is a potent
nucleophile in comparison to other groups (Figure 3) (Edwards
& Pearson, 1962). Several approaches of a free thiol or
protected thiol have been developed for thiolation (Figure 4) .
The choice of the cross ~ linking reagent is critical to
the success of conjugation. The reactive groups in cross~
linking reagents can be identical or different providing
diversity of reagents to bring about covalent bonding between
any chemical species. '!he cross-linking reagents capable of
reacting with the side chains of the amino acids of Abs for
conjugation may be classified into hOtOClbifunctional,
heterobifWlctional, and zero-length cross-linkers. Over three
hundred cross· linkers have been synthesized. The diversity of
tlK~se linkers is created by researchers for various
-Nfl, ~-C-OH -S-H -S-CHa
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-0-0H <=0
H
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Adapted from Wong, 1991
Figlfe 2. Reactive groups of amino acid side chains. Functional grol4's
A to Fare the six mosl reactive entities. G and H are less reactiw.
RS">Ar$ > RNH"> RO'> HO'>ArO'> RNH2 >~O
Adapted from Wong, 1991
Figlre 3. NudeophiUcity ofdifferent nucleophiles. Thiolate
is the most potent nucleophlle.
A.
~H"C"
o-S-S-CH2CH:2-c-O-CH3
E.
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Melhyl314-pyfid)'1ditJio)j:lropionimidate hydrocHoride S·acetylmercaptosucdrican¥ride
o
B. Ii
o-S-S-CH,CH,J-o-r F. oCH,-8-NH-Y
c.
Succirimidyl3-(2.p;rridytditllo)propionate
o 0 ,J,CH,-8-S-CH,CH,-Il-Q-N
r
Su::ei rimidyl acetyllhioproplonale
N.Acelylhomocysteine thIolaetone
G.
N~·CI·
HS-CH,CH,-8-o-cH,
Mel1Ty13-mercaplopropionimidale
D.
o 0
~~-CH'CH'-S-S-CH'Cf"J-o-?
Dilliobis(su:cilimldypropionate)
Figll'e 4. Common reagents used for thiolation, The reagents A to Econtain protected
thlol groups which can be activated 10 generate free thiols after proteinthiolation. Free
\hiol groups can be added to proteins directlylNith reagents Fto H.
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applications.
I 5.2 The Linkage of Cytotoxic Imlgs to Monoclonal Antibodies
The purpose of linking cytotoxic agents to MAbs is to
direct an agent selectively against antigen-bearirr,' cells. 1\
huge arrount of literature dealing with the problems and
methods of cytotoxic agents conjugated to MAbs has been
accumulated, extensively reviewed and discussed (Goose, Blair
& Kulkarni, 1983; Blair & Ghose, 1983; Ghose & Blair, 1987;
Pietersz, 1990).
For AMl', an ideal conjugation method should 1) not
interfere with either the agent or antibody activity; 2) allow
high incorporation of the drug; 3) avoid fOrTTBtion of
~lyrners of antitody or agent; 4) avoid aggregation of the
conjugate; and ~) be tedmically straightforward and
reproducible (Ghose, Blair & Kulkarni, 19B3). Three
strategies have been adopted: 1) direct covalent attachment of
the drug to Ab, e.g. carl:xx:liimides; 2) using a linker between
the drug and Ab, e.g_ glutaraldehyde; and 3) attachment of the
drug to a high~rrolecula:r· weight carrier rrolecule and then
conjugating to Ab, e.g. dextran and albumin.
Anthracycline antibiotics play an important role in
cancer treatment and represent one of the most investigated
classes of antitumor agents. The development of
anthracycline-MAb conjugates has been reviewed and sUl'lTl1arised
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by Hermentin and Seiler (Hermentin & Seiler, 1988). The
functional groups suitable for conjugation in Dau and Dox
include the daunosamine and the aglycon side chain (Figures 5-
8) .
'!he amino group-containing drugs, doxorubicin (Dox) and
daunomycin (Dau) , can be directly linked to the free carooxyl
groups of MAbs in the form of an amide bond by using water
soluble carbodiimide, EDCI (1-ethyl-3- (3-dimethyl-
aminopropyll-carbodiimidel (Hurwitz et aI, 1975). Another
approach is the use of small spacer molecules as a cross~
linker, glutaraldehyde, to couple Dau or Dox to the amino
groups of lysine in MAbs (Hurwitz et aI, 1975). Both
reactions are easy to perfol1ll and appear to be the most
attractive approaches. The major problem using these reagents
is polymerization. It is also difficult to reproduce these
couplings. Thus, the procedure for conjugation and the use of
cross-linking reagents are stressed.
The chemical linker, which is the heart of the conjugate,
determines the activity of tl".e drug either as an integral part
of the conjugate or as a releasable component of the
conjugate. The choice of a releasable linkage is essen1:ial
for Dox les because the full activity of Dox is required in
the free drug form. The development of hydrazone linkers has
been shown to allow release of the unm::xiified drug under mild
acidic conditions (Greenfield et al, 1990). A number of
5~
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to NH R---:c==aD,"~O O~R'
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D,"~O R~H
19-NHCO(CH')'-N~ S"" 19
o Adapted from Hermentin & Seiler, 1988
Figure 5. Conjugation via N-acylalion oflhe daU10samine lJ1it
R=H : dall1orubicin: OH: doxorublcln
Sa EDCI/Ig (HlIVoilzelal.1975)
5b GMBS I reduced Ig (Fujiwara, YaslD1O& Kitagawa, 1981)
5c poly·L·gllltamic acid Ilg-maleimide (Kato et ai, 1984)
5:1 oligopeptide spacers I EDCI/Ig (Trouel et ai, 1982)
5e cis-aconiticanhydride/EDCIIIg (Shen& Ryser, 1981)
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~LH,R
~'O"
~ ~~ OH" "I ~~~iJFf::1 H H
'"
.A:b , I 6~:,O
e:rfJ CHril CH,(l!
~ ~DeXlran IgDextran
(oxidized) (oxidized)
6b'j.......,0
e:rr:J
\oextran-Ig
(modlfted)
Adapted from Hennentin & Seiler, 1988
Figure 6. Conjugation via N*alkylation of the daunosamine unit
R =H: daunorubicln; OH: doxorubicin
6a: glutaraldehyde Jig (Hurwitzel aI, 1975)
6b: Nal04 - oxidized dextran; 6b': NaBH4/1g (Bernstein et ai, 1978)
6e: NaIO,; 6e': NaSH., / ~ (HUlwitz el 31,1975)
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Adapted from Hennentin & Seiler. 1988
Figure 7. Conjugation '-'8 the agl}oJ......side chain at C-14
R=Br
7a: Amino groups of Ig (GaUego et ai, 1984)
7b: 3-mercapto-2-hydroxy,lropyldextran (Hurwitz at aI, 1980)
7c: Carboxyl gr0l4>s ofPAA (Zunino etar, 1982)
(pLGA)
'T'
O~:
N
lH ~~C»OH ~
'~''O
~yS"'S~O"""N
V ......N~ ~CH.1:0Hl)"OH
ab' "'0
Figure 8. Conjugalion~a the aglycorHide chalnatC-13
R= H:daunorubicln; OH :doxorubicin
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8a Polygllrtamylhydrazide (HtuWitz et aI, 1980)
8b l-Aminooxy-4-((3-ri\(()pyridlr>-2-yl)dithiojbutane-HCI
ab' on I N-succlnlmldyl-3-(pY'idyldithio)propionate (SPDP)-1g (Brasrawskyetal, 1991)
8e SPOP; 8e'; onISPOP-~ (Greenfield etal, 1990)
ad Carboxymethyldexlranhydrazide (Hurwitzetal, 1980)
Be N·Maleoyl-6-aminocaproylhydrazide-HCI (VVillner et ai, 1993)
39
different linkers have been developed for this purpose.
Heterobifunctional cross-linking reagents are particulal"ly
useful for conjugation. The different reactivities of the
reactive groups permit the coupling procedure in a stepwise
manner, allowing purification and characterization of
intermediates before the final conjugation.
I 6.0 EFFICACY OF ANTIBODY-DRUG IMMUNOCONJUGATES (ICs)
Conjugation of cytotoxic drugs to m:::moclonal antitxxiies
for use in cancer therapy is gaining more attention because
many rcs have shown anti-tumor activity in both in vit.m and
in vivo models (Ford & casson, 1986). In vitro ICs are
generally less effective than the free drug, but it is not
necessarily correlated to in vivo potential as shown for VDS
ICs (Rowland et aI, 1985; Casson et aI, 1987) and Dox Ie
(Dillman et aI, 1986). Greater efficacy in vitro and in vivo
compared to the free dnlg has been reported with CBL ICs
(Smyth, Pietersz & Classon et al, 1986). The major problems
with irrmmoconjugates have been their low potency, poor access
and the JW1A respc..lse. It is very irrportant to focus on the
factors affecting and improving efficacy.
An improved retention of therapeutic agents on the
surface of target cells or the enhanced internalization of
such agents into target cells will be important. The ways to
attain these purposes include: 1) enhancing antibody affinity
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for TAA, 2) increasing Ab uptake into turror cells; and 3)
decreasing desorption from tumor sites. The vasoconstrictive
agents that can change the turror-to-normal tissue perfusion
ratio enchance the access of rcs to tunor (Symth, Pietersz &
McKenzie, 1987). By utling tumor necrosis factor, the
antitumor effect and tumor localization of rcs can be enhanced
(Symth, Pietersz & McKenzie, 1988). The use of aryl
carbohydrate adducts cf a radioiodinated Ab that increases
intracellular retention (Ali et al, 1990) may be a hint to
design some agents for increasing cell surface retention and
internalization of therapeutic agents. The attachment of
ana1og-s of the peptide "glutamic acid-alanine-leucine-a1anine"
(GAlA) to Fab of NR-MlrOS and NR-W-10 MAbs has been shown to
enhance the retention and internalization of these Fab
fragments by turror cells (Anderson et aI, 1993). These
approaches \M.y be useful to increase the efficacy of AMI'.
The loss of ilTl11Ufloreactivity of MAbs after the high
loading of drugs limits rc efficacy. One approach to this
problem is to utilize mac!OIOOlecules such as dextran and
albumin (Tsukada, Kate & Unemoto, 1984; Garnett & Baldwin,
1986; Shih & GOldenberg et aI, 1991, Heindel et aI, 1991) for
high levels of drug substitution and then to link the drug
conjugates to M1\bs. The major advantage of these rcs is the
potential for high substitution of drugs per MAb without
significant loss of inmunoreactivity.
Most drugs rrnlst enter tUllOr cells to exert; an effect.
Thus, the degree of Ie taken up is critical for cytotoxicity
at the tumor site. The evidence of Ab intentalization after
specific binding has been dF.monstrated (Matzku et aI, 1988,
Tsaltas, Ford & Gallant, 1992). There has been experimental
evidence that Dome drug-Ab rcs are endocytosed (Hermentin et
aI, 1990). Once intracellular, the ideal Ie can exert toxic
effects even with the drug remaining covalently round to MAb;
however, drugs such as anthracyclines in the form of IC may be
inactive unless they are cleaved frem MAb as free drug. The
findings of the acid-sensitive hydrazone linker in Dox ICs
suggests that the release of free Dox from MAb in acidic
intracellular compartments would be the important step in the
action of Cox res (Greenfield et aI, 1990; Braslawsky et aI,
1990 & 1991; Trail et aI, 1992 & 1993). Deconjugation via a
chemical enzymatic process in the intracellular
compartment, lysosome, to release the free drug,; will become
the najor approach to design the anthracycline rcs for
improving therapeutic efficacy. Another avenue to increase
the efficacy of rcs is the linking of more potent antiturror
agents to MAbs for targeting. One of the Dox derivat i ven, 3'-
deamino-3' - (4-iTOrpholinyl) doxorubicin (MRA) , has been
conjugated to MAb IM609 for in vi tro testing (Mueller,
wrasidlo & Reisfeld, 1990). The use of idarubicin-MAh
conjugates has shown the co:nplete eradicat.ion of srraller
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turrors in a human xenograft roodel (Pietersz et aI, 1988). The
high specific cytotoxicity of maytansinoid conjugates toward
turror cell lines and low systemic toxicity in mice may open
more effective treatments of human cancer (Chari et aI, 1992)
Clinical studies have been performed to study the
feasibility of AMI' in cancer therapy. In these studies there
was no toxicity of conjugates administrated to patients, but
the results were not really encouraging. Moreover, Dox
irrrnunoconjugates showed toxicity in clinical trials. The
toxicity was likely due to the Dox non-covalently attached to
antil:xxiy and the drug was released frem the conjugate to cause
the toxic effect in patients (Oldham et aI, 1988). The major
impediment of AMT for the treatment of cancer is the HAMA
response (Khazaeli et aI, 1988; Tjandra et al. 1990; Petersen
et al, 1991). Genetic engineering techniques are being
evaluated as a way of overcoming the problem of the HAMA
response by producing chimeric. partially human or totally
human antibcxiies (LoBuglio et al, 1989; Gorman et ai, 1991;
Persson et al, 1991; zebedee et al, 1992; Gram et al, 1992).
4J
I 7.0 OBJECTIVES OF THESE STUDIES
Targeted chemotherapy using MAb offers a potential avenue
to improve site-specific drug delivery to the tumor site. The
objectives of this project were: 1) to develop the chemistry
of heterobifunctional spacers for linking to cL.l.lg; 2) to
develop the conjugation conditions for linking drug-spacer
derivatives to rronoclonal antibody; and 3) to test the
efficacy of drug-monoclonal antibody irrrrru.noconjugates in
vitro.
CHAPTER II : SYNrHESIS OF HETEROBlFUNCTIONAL SPACERS
AND DOXORUBICIN DERIVATIVES
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II 1.0 INTRODUCTION
The development of monoc~_onalantibody-drug (doxorubicinl
conjugates (irrmunoconjugates) has emerged during the past
decade. Because of the conventional problems in lUlwanted
cross-linkage and polymerization of the antibody and dnlgS
during conjugation, the new methods of chemical attachment of
doxorubicin to MAb is stressed. Heterobifunctional cross-
linking reagents increasingly used for their
regiospecificity in coupling drug to MAll for il1Tl1lU1otargeted
chemotherapy. The rrodification of daunorubicin (Dau) in 3 I -
amino group with p- (isothiocyanato) benzoyl chloride and p-
(isothiocyanatol phenypropionyj chloride reaul ts in 3' - N-amide
analogues and the inmunoconjugates from these Dau analogues
have shown selective toxicity for hul'I\3.o ovarian cancer cells
(SweE'!t et aI, 1989; Rosik & Sweet, 1990). The
maleimidobenzoyl spacers have proved to be useful in the
preparation of anthracycline-MAb conjugates (Hermentin et al,
1990). The inmunoconjugate containing the doxorubicin (Dox)
derivative, maleimidocaproyl doxorubicin hydrazone, were
derronstrated to have antigen-specific cytotoxicity in vitro
and to produce complete tUlT()r regression in vivo (Trail et aI,
1993; Willner et at, 1993). Therefore, we designed and
synthesized a series of new 1M1eimidobenzoyl cross-linking
agents which enable the conjugation of 3' -amino group and 13-
keto position of Dox to thiolated Will, resulting in stable
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conjugates for targeted chemotherapy.
II 2.0 HETEROBlFUNCl'IONAL CROSS-LINKING REAGENT SYNTHESIS
The first spacer maleimidobenzoic acid (MBA) (31 was
conveniently synthesized from 4-aminobenzoic acid (1) ,
requiring only two synthetic steps as shown in Scheme 1.
Treatment of 1 with 1.15 molar equivalent of maleic anhydride
in acetone/methanol, provided intermediate 4-carooxy-
maleimidobenzoic acid (CNBA) (2) in good yield (95\).
Cyclodehydration of 2 with acetic anhydride as the reagent and
solvent, with sodium acetate, followed by hydrolysis, gave the
product 3, also in good yield (78%). Both 2 and 3 were
obtained as crude products and detected as a single spot on
'TIC. From lH NMR spectroscopy, 2 and 3 were pure and the
purity was confirmed by microanalysis.
Two new maleimidobenzoyl spacers, N- (4-maleimidobenzoylJ-
6-aminocaproic acid (MBCA) (4) and N- (4-maleimidobenzoyl) -11-
aminoundecanoic acid (MBUA) (5) were prepared directly by
coupling of 3 to comnercially available amino acids, 6-
aminocaproic acid and ll-aminoundecanoic acid respectively,
utilizing a procedure by Eirkofer and Ritter with
l,l,l,3,3,3,-hexamethyldisilazane (HMO) as the silylating
agent and solvent (Birkofer & Ritter, 1965). Scheme 2
provided an outline of the synthetic steps leading to 4 and 5
starting from 3 and 6-aminocaproic acid or l1-aminoundecanoic
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acid.
Trimethylsilylated 6-aminocaproic acid which was lI'Cisture
sensitive was prepared under inert condition. 6-Aminocaproic
acid was refluxed under nitrogen with 1.1 molar equivalent of
HMO and two drops of concentrated sulfuric acid, followed by
the addition of triethylamine (TEA) and chlorotrimethylsilane
('IMSCl) in benzene and stirring overnight at room temperature.
Activation of 3 by 1.1 equivalent of isobutyl chloroforrnate
with 1.1 equivalent TEA as hydrogen chloride acceptor at O''C,
followed by coupling to silylated 6-aminocaproic acid (2.0
equival~nt), followed by mild hydrolysis, gave the product 4
and starting material detected on TLC. After work-up and
flash chromatography, 4 was obtained in 49% yield. The
synthesis of 5 was similar to 4 except 1. 6 molar equivalent
HMO was used. This synthesis gave 46% yield. Analysis of the
IH !'l-1R spectra of both .4 and 5 showed a sharp singlet of the
maleimido group at 7.2 ppm, integrating for two protons.
Other two new maleimidobenzoyl spacers, 4-maleimido-
benzohydrazide trifluoroacetate salt (MBH) (15) and N- (4-
maleimidobenzoyll -6-aminocaprohydrazide trifluoroacetate salt
(MBOI) (16), were prepared directly from MBA (3) and MBCA (4)
respectively by converting the carboxylic acid group to
protected hydrazide and then following the treatment of
trifluoroacetic acid, using a procedure rrodified from Willner
et al. (Willner et aI, 1993). Scherre 5 provided an outline of
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the synthetic steps leading 15 and 16 starting from 3 and 4
respectively.
Activation of 3 by 1.1 equivalent of isobutyl
chlorofonrate with 1.1 equivalent TEA as hydrogen chloride
acceptor at DOC, followed by coupling to tert-butyl carbazate
(1. 0 equivalent) at room temperature gave the crude protected
hydrazide, 4-maleimidobenozic acid (tert-butyloxycarbonyll
hydrazide (13). After work-up and flash chromatography, 13
was obtained in 60% yield. The synthesis of N- (4-
maleimidobenzoyl) -6-aminocaproic acid (tert-butyloxycarlxmyll
hydrazide (14) was the same as the procedure ab:Jve with the
starting material 4. This synthesis gave 72t yield. The
protected hydrazide 13 and 14 were converted to hydrazide
trifluoroacetate salts, 15 and 16 respectively, in ice-cold
trifluoroacetic acid (TFA). Analysis of the lH NMR spectra of
roth 15 and 16 showed a sharp singlet of the maleimido group
at 7.2 ppm, integrat.Lng for two protons.
II 2.1 Doxorubicin-Spacer Coupling Reactions
TIle heterobifunctional spacers, 3, 4 and 5, were used to
couple doxorubicin at 3' -NH2 position to form the 3' -amide
bonding. The doxorubicin containing the free-base were
obtained by treating doxorubicin hydrochloride (Dox' Hell with
5% sodium bicarbonate. Selective amide formation of 3' -NH2
with the various activated maleimidoyl spacers (3,4,5) (Scheme
<19
3) was achieved under mild reaction conditions. The desired
coupling products, 3' -N-acyl doxotubicin derivatives (7,8,9),
were purified by preparative thin layer chromatography and
obtained in 41-51 % yield.
The coupling reaction of rraleimidobenzoyl spacers, 15 and
16, to l3-keto position of doxorubicin were achieved by mixing
the spacers and Dox' Hel with a catalyzed arllOW1t of
trifluoroacetic acid (TFA) (Scheme 6) at RT for 1 day. TIle
products, 13-acyl hydrazone doxorubicin, were precipitated Ollt
by the addition of acetonitrile and obtained in 85-95 % yield.
Desired product can be further purified by TLC.
II 3.0 DISCUSSION
The ma.leimido derivatives, MBA, MBCA and MBUA, were
designed to cross-link the amine group of Dox to thiol groups
of antib:::ldy. MBA was synthesized using an established
literature method and was obtained in an easy way without any
purification. Before using I, 1, 1, 3, 3, 3 -hexamethyldisilazine,
several synthetic approaches were unsuccessful in preparing
MBCA and MBUA. The major problem was the insolubility of the
amino acids in ordinary organic solvents such
dichloromethane and THF in performing the coupling reaction.
We tried a polar solvent, hexamethylphosphoramide (Hfv1PA) , but
the coupling reaction was still Wlsuccessful. Thus, another
synthetic approach outlined in Scheme 4 was adopted. However,
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the maleimide was unstable in alkaline condition and
converted to maleamic acid before the hydrolysis of the ester
bonding. The conversion was rapid and only a single spot was
detected on TI.C. We believe that the driving force of this
reaction is the release of ring tension upon opening. The
product \tJaS identified as 12 from lH NMR.
The most prominent feature of the organosilicon compounds
is the excellent solubility in organic solvents. Substances
that are insoluble in organic solvents because of the presence
of -NH~, -CONH2 • -OH, -C02H groups, etc. become readily soluble
in these solvents with the replacement of their protons by the
trimethylsilyl group. 1,1,1,3,3, 3-Hexamethyldisilazane is a
suitable reagent for direct trimethylsilylatia:1 of amino acids
which can not be silylated with trimethylchlorosilane, because
of their zwitterionic character. TIle trimethylsilyl amino
acids are soluble in ordinary organic solvents; thus,
reactions can be carried rut in a horrogeneous organic phase.
In these organic syntheses, the activated carboxylic acid
group can be regioselectively coupled to the silylated amino
group of amino acids without the formation of the anhydride
tending with the carboxylic acid group. After the coupling
reaction, the free carboxylic acid group can be easily
recovered by hydrolysis of sHyl ester with water. The major
problem of this methodology is that the reactions do not
proceed completely, some starting mat""rial (3) is present even
TFA, giving stable
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by using an excess of silylated amino acids. '!his problem is
lTDst likely due to the very unstable nature of the silylated
amino acid towards hydrolysis, durirg the various reaction
I"aIlipulation steps. we believe that if these reaction \o'el-e
perforned completely in a glove box, high yield of the desired
products would be obtained.
The maleimido 6pacers, MBH and MBO!, were designed to
couple the 13-keto group of Dox to thiolated antiJ:xxiy. These
spacers, 15 and 16, were synthesized from 3 and 4 respectively
via the protected hydrazides, 13 and 14 (Scheme 5). The
maleimide can be condensed with either tert~butyl carbazate oc
hydrazine. losing the typical maleimide vinyl proton resonance
(Heindel et aI, 1991). This suggests the competitive Michael
addition of the carbazate and hydrazine to maleimide have
occured. Moreover, at equimolar concentrations of activated
spacers. 3 or 4. and tert-b.1tyl carbazate reacted at room
temperature to give stahle protected hydrazide. Maleimide waF;
stable in acidic condition; thus, N-protection with teet-
butoxycarbonyl group was adopted. The tert-butyl protective
group was rentWed in
trifluoroacetate sal t.
'These heterobifunctional spacers consist of two reactive
functional groups, maleimide with cartoxylic acid or
hydrazide, separated by phenyl, N-benzoylpentyl or N-
benzoyldeC'.I1 spacer. TIle N-benzoylpentyl and N~benzoyldecyl
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spacer arms should limit the possibility of sterk hindrance
between Dox and MAb. 'The maleimide and carboxylic acid
functional groups were chosen because they show .:he desired
reactivities with amines and thiols respectively. Moreover,
these groups are chemically compatible, yielding stable cross-
linking reagents. The maleimide and free hydrazide are not
compatible to each other. Thus, the hydrazide is cOlTplexed
with TFA to form the stable salt and to prevent the self
condensation reaction.
All maleimido derivative spacers, 7, 8, 9, 15 and 16 are
easy to prepare and stable during handling. The spacers, 7 I
8 and 9, are very useful to couple drugs containing amino
groups to proteins containing thiols and the resulting amide
and thioether oonding provide stable linkage of the conjugate.
Various reagents such as N-hydroxysuccimide or thionyl
chloride can be used to activate the carboxylic acid group of
the linker. However, acid chloride is too reactive and could
react with the -OH group in Dox. The N-hydrm...ysuccimide
derivative is less reactive and rrpre selective towards the NH2
group in DoXi however, the reaction rate will be slow and this
may lead to the conjugation reaction between the amino group
of Dox and the maleimide rroiety of spacer. Thus, isobutyl
chloroformate is the preferred reagent to activate the
spacers. The reaction time, less than 30 minutes, is enough
for the coupling reaction. The spacers are regioselectively
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introduced to Dox in an straightforward nannel- and in
reasonable yield.
The hydrazide spacers, 15 and 16, are not very react i ve
to the keto group of Dox. The addition of catalytic amounts
of TFA accelerates the condensation reaction without acid-
catalyzed deglycosidation of Dox. The isolation of C-13
hydrazone derivatives of Dox was simple and involved
precipitation by the addition of acetonitrile.
MA
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2
,. Ae,O
AcO"Na+ I /:).
2.H,O,6
Scheme 1. Synthesis of 4 -earboX'jimaleirnidobenzoic acid (2)
and 4-maleimidobenzoic acid (3)
4, R =-(CH2.-
°
[ r~N--©-C~NH_ R_CJ'° ]'l' 'O-SiMe3j H20
Scheme 2. Synthesis ofN-{4-maleimidobenzoyt)·6-aminocaproicacid (4)
and N-(4-maleimidobenzoyl}-11-aminoundecanoic acid (5)
56
3,7 :
4,8 :
5,9 :
R=-<Q)-
\I
/" ,,,",,,,_ /"- "C--eH,OH
"00
6
7,8,9
Sclleme 3. Synthesis ofdoxorubicin 3'-N·amide derivati~s (7,8,9)
57
3
H,N-ICH2),-CO,H
MeOH
SOC~
_. #,0
Cl H3N-(CH2)S-C ..........
O-CH3
10
11
12
Scheme 4. Base-hydrolysis of maleimJdobenzoyt ester
58
qo ,,0N-R-C'OH
°
1. TEA
CIC02iSU
2. H,NNHCO,tau
13,14
CF,Co,H
qo ,,0N-R-C
'NHNH,· CF,Co,H
o
13,15: R= ---0-
o
14,16: R= -o-!-NH(CH,J'-
15,16
Scheme 5. Synthesis of 4-maJeimidobenzohydrazide trifiuoroacetale
sail (15) and N-(4·maleimidobenzo~)-6-aminocaprohydrazjde trifluoro-
acetate sall(16)
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Go ,faN-R-C,NHNH, 'CF,CO,H
a
15,16
15,17 : R = ---0-
1
16,18 : R = ~-NH(CH:),-
17,18
Scheme 6. Synthesis ofdoxorubicin C-13 hydrazone derivatives (17,18)
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II 4. 0 ElXPERIMENI'AL
Materials. Anhydrous reactions were performed under an
inert atrrosphere of nitrogen. Unless otherwise noted,
starting material, reactant and solvents were obtained
c~rcially from Aldrich and were used as such or purified
andlor dried by standard means (Perrin & Armarego, 1988).
Organic solvents were dried over magnesium sulphate (MgS04)'
evaporated on a rotat.ory evaporator and under reduced
pressure. All reactions ....·c:':re monitored by thin-layer
chromatography (TLC). The plates were visualized by U\l
fluorescence'. Comnercial 'ILC plates were Signa. T6145
(polyester silica gel 60 A (O. 25m). Flash chromatography was
performed according to the method of Still and coworkers
(Still et al.) on Merck grade 60 silica gel, 230-400 mesh.
Melting points (mp) were recorded on an Electrothermal 9100
apparatus and are uncorrected. The infrared spectra (IR) were
taken on a Nicolet mojel 205 Fl'~IR spectrophotometer. Mass
spectra assays (MS, m/e) were obtained using a VG Micomass
7070 HS instrument with an ionization energy of 70ev.
Elemental analyses were conducted by Microanalysis
Laboratories Limited, Markham, Ontario. Nuclear magnetic
(NMR) spectra were obtained in deuterated
dimethylformamide, dimethyl sulfoxide, acetone or chloroform
on a General Electric GEl 300-NB (300 MHz) instrument: chemical
shifts were measured relative to internal standards:
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tetramethylsilane ('!MS, a 0.0 ppm) for lH and lIe NMR.
Multiplicities are described by the following abbreviations:
s (singlet), d (doublet), t (triplet), q (quartet I, m
(multiplet) and so on. The NMR assignments were aided by 'H~
L3c correlation (HETCORR) 2-D spectra.
4-Carbaxylmaleimidobenzoic acid (CMBA) (2)
4-Aminobenzoic acid (l) (20 g, 146 rrmoll suspended in
anhydrous acetone (120 ml) was solubilized by the addition of
distilled methanol (20 ml). Then, maleic anhydride (16.49 g,
168 nmol) in anhydrous acetone (40 mIl was added dropwise and
stirred at room temperature for lh. The yellow precipitate
was filtered, washed with 100 ml acetone, and vacuum-dried to
yield 32. 70g (95%) of 2 : mp 242-243-"Ci IR (KBr) 3500-2500
(~H), 3325(NH), 1700 (C=O) cm-1 ; 'H NMR (I»1S0-dd 0 12.84 (bs ,
2H, AT, ~H), 10.61 (8, IH, NH), 7.91 and 7.74 (two ct, 4H ,
J~8.7 Hz, para-substituted phenyl group), 6.50 and 6.33 (two
d, 2H, J=12 Hz, rraleimido-H): He ~ 0:11180-4,) a 166.88 (2),
163.63, 142.73, 131.64,130.19 (2),125.52,118.69 (2); MS,
role: 235 (M') Anal. Calcd for ell~NIC\: C, 56.17; H, ].86; N,
5.96:. FOWld: e, 56.22: H, 3.92: N, 6.03.
4-MaleiJni.dobenzoic acid (MBA) (3)
The yellow powder of 2' (20g, 85 rmol) was treated with
acetic anhydride (40 rol) and anhydrous sodium acetate D.4g,
6'
41.50 nmol) at SO"C for 2h until a clear solution was formed.
The solution was evaporated to dryness and stirred with water
(500 mIl at 70°C for 2 h for complete hydrolysis. The white
precipitate was filtered off and vacuum-dried to yield 14. 45g
(78%) of 3 : mp 238-239"Ci IR (KBrl 3350-2600 (COJI), l799 and
1715 (C=O) cm-l; lH NMR (DMSO·d,,) B 13.1 (5, lH, C02H) , 8.05
and 7.51 itllO d, 4H, J=B.5 Hz, para-substituted phenyl group)
7.23 (s, 2H, ma.leimido-H); lle NMR O:::MSO-ct} a 169.52 (2),
166.65, 135.50, 134.86 (2). 129.89 (2), 129.50, 126.11 (2);
MS, m/e: 217 (M') Anal. calcd for CllH,NIO~: C, 60.83; H, 3.25;
N,6.45. Found: C, 60.97; H, 3.36; N, 6.31.
N- (4-Maleimidobenzoyl) -6-aminocaproic acid (MBCA) (4)
Compound 4 was prepared directly from 3 by coupling to 6-
aminocaproic acid. A suspension of 6-aminocaproic acid (3.00
g, 22.87 rrrrol) in 1, 1, 1,3,3, 3-hexamethyldisilazane (5.31 mI,
25.16 nmol), containing 2 drops of concentrated sulfuric acid,
was heated at reflux (12D-130OC) under nitrogen until complete
dissolution. Afterwards, the reaction mixture was boiled for
a further 30 min. After cooling, benzene (30 rol), TEA (1.14
ml, 7.62 mooll, and'IMSCl ( 0.97 ml, 7.62 mool) were added and
the mixture was stirred overnight at room temperature to yield
the trimethylsilyl ester of N-trimethylsilyl-6-aminocaproic
acid. The p::>Wder of 3 (2.48 9, 11.44 mool) was suspended in
40 ml dichloromethane and cooled to DOC before the addition of
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TEA. (1.75 ml, 12.56 TtIOCll) and isobutyl chloroformate (1 63 1II1,
12.56 1lIl'01). The mixture was stirred for Ih at OT and then
added to a solution of silylated inter1l\ediate in 25 m1
dich1oromethane. Stirring was continued for 4 h at l:Oom
temperature. The reaction mixture was diluted with ethyl
acetate (200 mll I washed with 0 .IN Hel (2 X 100 ml), saturated
NaCl (2 X 100 mll, then dried (MgS04) and evaporated to give
crude rraleimide. The product was purified by flash
chromatography, using two mixtures of solvent (0.1:1:3 acetic
acid/acetone/hexane then 0.1:2:3 acetic acid/acetone/hexane)
to yield 1.68 g (49%) of 4: mp 156-157"C; IR (KBr\ 3500-2500
(C02H) I 3466 and 3318 (NH), 3086 (Ar), 2931 and 2868 (alkane)
and 1701 (C"'O) cm· 1 ; lH ~ (DMF-d,) {) 8.55 (t , IH, J"'S.2 Hz,
NH), 8.07 and 7.53 (two ct, 4H, J=8.5 Hz, para~substituted
phenyl group), 8.03 (5, lH, C02H) , 7,24 (5, 2H, rraleimido-H),
3.39 (qapparent, 2H, J=6.8 Hz, CH2Nj, 2.30 (t, 2H, J=7.3 Hz,
rn~CO), 1. 62 (m, 4H, QI~ x 2), 1.43 (m, 2H, Q-I~); lie NMR (I:M["-
d7 ) 6175.15,170.42 (2), 166.31, 135.46 (2), 134.98,134.76,
128.40 (2), 126.78 (2), 40.08, 34.34, 29.81 (superimposed with
the solvent peak), 27.04, 25.29; MS, m/e: 330 (M'l. Anal.
calcd for C17H18N20s: C, 61.81; H, 5.49; N, 8.48. Found: C,
61.69; H, 5.39; N, 8.33.
N- (4-MaleiInidobenzoyll-ll-a.:li.noundecanoic acid (MBUA) (5)
A suspension of 11-aminoundecanoic acid (3.00 g, 14 ~o
6'
fTDTlQl) in 1,1,1,3,3,3-hexamethyldisilazane (5,03 ml, 23.84
nmol), containing 2 drops of concentrated sulfuric acid, was
heated at reflux (120-130OC) under nitrogen until complete
dissolution. Afterwards, the reaction mixture was boiled for
a further 30 min. After cooling, benzene (20 ml), TEA {O.69
mI. 4.94 rrrnoll, and'IMSCl (0.63 ml, 4.97 Tm'Ol) were added and
the mixture ,""os stirred overnight at room temperature \0 yield
the trimethylsilyl ester of N-trimethylsilyl-n-
aminoundecanoic acid. 'llie powder of 3 (1.62 g. 7.46 rrmol) was
suspended in 30 rol dichloromethane and cooled to DOC before
the addition of TEA (1.14 ml, 8.18 rrrnoll and isobutyl
chloroformate (1.06 rol, 8.20 rrrnol). The mixture was stirred
for Ih at DOC and then added to a solution of silylated
intermediate in 25 ml dichloromethane. Stirring was continued
for 4h at room temperature. TIle reaction mixture was dil:lted
with ethyl acetate (200 ml), washed with O.lN Hel (2 X 100
mIl, saturated NaCI (2 X 100 mIl, then dried (MgSO~) and
evaporated to give crude maleimide. The crude product
adsorbed in silica gel (7 g) was layered on a silica gpl
column and was purified by flash chromatography with solvent
0.1:1:3 acetic acid/acetone/hexane then 0.1:2:3 acetic
acid/acetone/hexane to yield 1.38 9 (46%) of 5: mp 162-164OCi
IR (KBr) 3500-2500 (C02H) , 3473 and 3318 (NH), 30"79 (Arl, 2945
and 2868 (alkane) and 1715 (C..O) em-I; lH NMR (DMP-d7l 3 8.55
(t. 1H. J=5.4 Hz, NHl, 8_07 and 7.53 {two d, 4H, J;8.5 Hz,
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para-substituted phenyl group), 8.03 (8, lH, C02H) , 7.23 (5,
2H, maleimido-H) I 3.39 (q apparent. 2H, J"'6.9 Hz, Ot~N), 2.28
(t , 2H, J=7.3 Hz, OI~CO), 1.34 (rot 4H, Gl2 x 2), 1.4-1.25 (bs,
12H, CH2 x 6); llC NMR ([MF-d7 ) 0175.13, 170.41 (2), 166.30,
135.44 (2), 134.94, 134.79, 128.38 (2), 126.76 (2), 40.11,
34.36, 27.50, 25.54, six peaks hidden by solvent peak; MS,
role: 400 (W). Anal. Calcd for C~lHl8N2o,: C, 65.98; H, 7.05:
Nt 7.00. Found: C, 65.90; H, 7.01; N, 6.92.
Synthesis of 3' -N-amide derivatives of Doxorubicin (7,8,9)
Doxorubicin free base (6) (from 5 ml of 2mg/ml of Dox-HCl
salt in 0.9% saline, O.017nmol) was extracted with chloroform
from 1 rol 5% NaHCOJ illltil the aqueous layer was free of the
strong orange colour. The extracts were dried over Na:,sD.1,
filtered, and evap:n:ated, giving 9.37 mg, assuming 100%
recovery.
Synthesia of 3'-N"- (4-maleimidobenzoyl)doxorubicin (7)
MBA. (3) (0.2 g, 0.92 nrnolJ was suspended in 4 m]
dichloromethane and cooled down to DOC. TEA. (144 1-11, 1.0)
Tl'TOC.'l) and isobutyl chloroformate (132 ~l, 1.02 Irrrcl) were
added and stirred at OOC for 1 h. The activated MBA (150 Ill,
0.032 nrnol) was added to the Dox-NHl (9.]? 1ll3, 0.017 lmlC.l) In
Gf:lC12:MeDH (5 ml, 95:5) and stirred at room temperature for
0.5 h. The product was purified by TLC, using ('H~CljMeoH
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(9:1) and then scraped out. The silica gel containing the
desired product was washed with 0I2C12 /MeGH (20 ml, 9:1) and
filtered. After evaporating the solvent from the filtrate,
the residue was disBalved in 2 rol hot dichloromethane, cooled
down to room temperature and then filtered through cotton.
Ethyl ether was added drop by drop to the filtrate for
precipitation. After the rerroval of the solvent, the red
precipitate \-las dried under vacuum to give 5.23 IT9 (41%) of 7:
lH NMR (mel]) a 14.00 (s, IH, OH-ll) , 13.26 (s, lH, OH-G) ,
8.05 (d, IH, J" .. =7.2 Hz, H-l), 7.82 and 7.44 (two ct, 4H, J=8.5
Hz, para-substituted phenyl group), 7.79 (t, IH, J 1,2=Ju =8. 0
Hz, H-2l, 7.39 (d, IH, J, ..=8.4 Hz, H-3), 6.87 (s, 2H,
maleimido-H), 6.52 (d, IH, J=8.4 Hz, NH-3 '), 5.55 (d, IH,
J, .... =3.5Hz, H-l'l, 5.32 (m, IH, H-7), 4.79 (d, 2H, J::::4.6Hz,
QI~-14), 4.59 (5, IH, HO-4'), 4.35 (ro, IH, H-3'), 4.24 (q, lH,
J ...",,,,6.7Hz, H-5'), 4.07 Is, 3H, OCHJ }, 3.28 (d, lH, ,T, .. :~",18.5
Hz, H-lOPl, 3,03 (d, IH, J" ..",.p=18,5 Hz, H-lOex), 2.37 (d, IH,
J"...p",15 Hz, H-8P), 2.19(dd, IH, u,.•..=-3.8 H3, J .... p"'15 Hz, H-8ex}
1.32 (d, 3H, J., ... = 6.56 Hz, OIJ-6').
Synthesis of 3' -N- [N- (4-maleimidobenzoyl) -6-aminocaproyll
daxorubicin (8)
MBCA (4) (0,1 g, 0.30 tm"Ol) was susper1ed in 4 rol
dichloromethane and cooled down to DOC, TEA. (47 ?tl, 0.34
nrnol) and isobutyl chloroformate (43 Jotl, 0.33 rmol) were added
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and stirred at OOC for 1 h. The activated MBCA (348 pl. 0,026
mrol) was added to the Dox-NH2 (9.37 rrg. 0.017 nUlOl) in 5 ml
Ql~C12:MeOH (95:5) and stirred at room temperature for 0.5 h.
The product was purified by TLC, using QI.~Cl~/MeOH (9:1) and
then scraped out. The silica gel containing the desired
product was washed with Q!2C12/MeoH (20 ml, 9:1) and filteD=d.
After evaporating the solvent from the filtrate, the residue
was dissolved in 2 ml hot dichloromethane, cooled down to r<Xllll
terrperature and then filtered through cotton. Ethyl ether waG
added dropwise to the filtrate for precipitation. After the
removal of the solvent, the red precipitate was dried under
vacuum to give 7.57 rrg (51%) of 8; 1H toMR (CDCl,) a 13.96 (s,
IH, OH-lI)t 13.25 (5, IH, OH-6), 8.03 (ct, 1H, J, .. ~7.6 Hz, H-
1), 7.85 and 7.45 (two ct, 4H, J=8.6 Hz, para-substituted
phenyl group), 7.78 (t, lH, J,.,=J,.,=B.l Hz, H-2), 7.38 (ct, 1B,
J,..=8.2 Hz, H-3), 6.88 (s, 2H, maleimido-H), 6.46 (t, 1H,
J=S.B Hz, NH), 5.92 (d, 1H, J=8.6 Hz, NH-3'), 5.48 (s, 1H, H-
I'), 5.27 (m, lH, H-7), 4.75 (d, 2H, J=4.8 Hz, a1~-14J, 4.60
(s, lH, HO-4'l, 4.13 (m, 2H, H-3', H-5'J, 4.07 (S, 3H, 001,),
3.45 (m, 2H, 0i2N} , 3.27 (d, 1H, J ..... ,.p=18.0 Hz, H-lOpJ, 3.0/.
(ct, lH, J,.....,"'18.0 Hz, H-IO«), 2.35 (d, lH, J=14.7 Hz, JI-af.}l,
2.17(m, 3H, H-Ba, DiP), 1.24 (d, 3H, J .... =6.5 Hz, Q-1,-6'J.
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Synthesis of 3' -N- (N- (4-maleimidobenzoyl) -11-aminoundecanoyl
doxonJbicin (9)
MBUA (5) (0.2 g. 0.50 rmol) was SUspended in 4 ml
dichloranethane and CCX)led down to O"C. "l'E'A (77 iiI, 0.55
mroll and isobutyl chlorofonnate (72 Jil. 0.55 ntrol) were added
and stirred at. we for 1 h. TIle activated MBCA (2001-11, 0.027
rmoll was added to the Dox-NH~ (9.37 TTg, 0.017 rmoll in 5 ml
Gl~Cl~;MeOH (95;5) and stirred at room temperature for 0.5 h.
lhe product was purified by TLC, using Q{2C1J!MeoH (9:1) and
then scraped out. Ihe silica gel containing the desired
product was washed with CH2C12 /MeOH (20 ml, 9:1) and filtered.
After evaporating the sohent from the filtrate, the residue
was dissolved in 2 m1 hot dichloranethane, cooled down to room
tent>erature and then filtered through cotton. Ethyl ether was
added drop by drop to the filtrate for precipitation. After
the rerooval of the solvent, the red precipitate was dried
Wlder vacuum to give 7.13 rrg (45\) of 9: IH NMR (crx:l}) 013.98
(5. IH, OH-ll), 13.25 (8, 1H, OH-6), 8.04 (d, 1H, J 1 •z=7.7 Hz,
H-1), 7.85 and 7.63 (t'ftO d, 4H, J=B. 5 Hz, para-substituted
phenyl group), 7.78 (t, 1H, J 1,2=JZ,3=8.0 Hz, H-2), 7.39 (d, 1H,
J 2 ,1=8.6 Hz, H-3), 6.88 (5, 2H, male imido-H) , 6.21 (t, 1H,
J=5.2 Hz, NH), 5.86 (d, 1H, J=8.6 Hz, NH-3'), 5.50 (d, 1H,
JI,.~,=3.7 Hz, H-1'L 5.29 (m, lH, H-7), 4.76 Cd, 2H, J=5.21 Hz,
Ql.~·14), 4.56 (s, 1H, HO-4'}, 4.15 (m, 2H, H-3', H-5'), 4.07
(5, 3H, CCHj ), 3.45 (m, 2H, O1zN), 3.28 (d, 1H, J:... , ,=18.6 Hz,
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H-IOP1, 3.03 (d, IH, J""""1''''18.6 Hz, H-lOal, 1.27 (m, ISH, 01,-
6', 0i2 x6).
6-Aminocaproic acid methyl ester hydrochloride (10)
To a stirred mixture of 6-aminocaproic acid (5.02 g, 38.3
mool) in absolute methanol (60 mIl at DOC, thionyl chloride
(8.4 ml, US rrmol) was added dropwise. The ice bath was
removed, and the mixture was heated at reflux for 4 hand
concentrated in vacuo. The product was crystallized from
ether-methanol to yield 6.64 g (95%) of 10: mp 113-11S''C; 1l~
(KBrl 3445 (NH), 2951 and 2670 (alkane) and 1732 (C=O) em I;
lH NMR (DMSO-ct) 0. 8.13 (bs, 3H, NHl'Cl-j, 3.59 (5, 3H, OCH,l,
2.31 (t, 2H, J=7.6 Hz, Q!2N) , 2.31 (t, 2H, J=7.3 Hz, O{,CO) ,
1.54(m, 4H, Oi:z x 2),1.31 (m, 2H, 01.2 ); °C!'MR {J:»r1S0-d.l 6
173.23, 51.28, 38.44, 33.02, 26.55,25.32,23.90; MS, m/e: 181
{WI.
N- (4-Ma!eimidobenzoyll -6-aminocaproic acid methyl ester (11)
Compounds 11 was prepared directly from 3 by coupling to
6-aminocaproic acid methyl ester (10). A. suspension of 3 (1
g, 4.60 mmol) in 30 ml dichloromethane was cooled to O"C
before the addition of TEA. (0.64 ml, 4.59 rrrnol) and isobutyl
chloroformate (0.6 ml, 4.63 llTI'Oll. The mixture was stirred
for Ih at Dee and then added to a &olution of 10 (0.86 g, 4.-/3
nmoll in 20 ml dichloromethane, containing 'lEA (0.66 ml, 4.73
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l11TIOl) . The reaction mixture was stirred for 2h at
temperature. The mixture was washed with Hp (30 mIl, a.IN
Hel (30 mIl, 5% NaHCOJ (2 x 30 mIl, Hp (30 mIl, then dried
fMgS04) and evaporated to give crude maleimide. '!he product
was purified by flash chromatography with solvent first 1:3
and then 1:2 acetone/hexane to yield 0.76 9 (48%) of 11: mp
83-85"C; IR (KBr) 3335 (NH), 3084 fAr), 2957 and 2865 (alkane)
and 1738, 1726 and 1709 (C=O) cm'l i lH NMR O::::MSO-c4l 58.54 (t,
H, J:::5.6 Hz, NH), 7.97 and 7.47 (twd, 4H, J=8.5 Hz, para-
substituted phenyl group), 7.21 {s, 2H, maleimido-H}, 3.59 (5,
3H, OC'H1 ), 3.29 (q apparent, 2H, J=6.7 Hz, aI2N), 2.32 (t, 2H,
J=7.4 Hz, OI~CO), 1.57 (m, 4H, 01" x 2), 1.34 (ro, 2H, 0l2) i llC
tf'1R (l:MSO-cll a 173.35, 169.68 (2), 165.49, 134.80 (2),
133.87,133.71,127.75 (2), 126.09 (2), 51.19,39.11,33.25,
28.78, 25.97, 24.24; MS, m/e: 344 (W).
N- (4-Carboxybnaleimidobenzoyl) -G-aminocaproic acid methyl
ester (12)
1.4 ml iN KOH was rrade up to 5 ml solution with H20 and
then added to conyound 11 (0.3 g, 0.87 rrrnol) in 5 ml THF. The
reaction mixture was stirred at OOC for 30 min. The solution
was neutralized with 0.1 N Hel (20 roll and extracted with
ethyl acetate (2 x 50 mIl, and then dried (MgS04) and
evaporated to yield 0.27 9 (85%) of 12: mp 173-175"Ci IR (KBrl
3400-2400 (CO~H), 3378 and 3287 (NH), 3044 (Ar), 2957 and 2878
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(alkane), 1721, 1703 and 1690 (C=O) em"l i lH ~ (CMSO-c(,) .5
10.55 (s, IH, C02H) , 8.36 (t, IH, J=5.6Hz, NH), 7.82 and 7.69
(two ct, 4H, J=8. 7 Hz, para-substituted phenyl group), 6.48 and
6.34 (t'WO d, 2H, J=!2 Hz, maleimido-H), 3.58 (s. 3H, 0Cl-I,),
3.23 (qapparent, 2H, J;6.7 Hz, Of2N) , 2.31 (t, 2H, J=7.4 Hz,
Gl2CO), 1.54 (ro, 4H, Q{2 x 2),1.33 (ro, 2H, Q1~)i I'e NMR (DMSO-
~) a 173.37, 167.01, 165.47, 163.43, 141.06, 131.41, 130.45,
129.66, 128.04 (2) I 118.57 (2), 51.22, one carbon hidden by
solvent peak, 33.23, 28.87, 25.60, 24.22; MS, role: 264 (M'·
98), 120 (M'-242).
4-Maleimidobenzoic acid (tert-butyloxycarbonyl) hydrazide (13)
CompoWld 13 was prepared directly from 3 by coupling to
tert-butyl carbazate. The powder of 3 (2.689, 12.3 rmx::ll) was
suspended in 60 ml dichloromethane and cooled to OT before
the addition of 'TEA (1.89 ml, 13.6 mrol) and isobutyl
chlorofo:ma.te (1.76 ml, 13.6 lTm)ll. The mixture was stirred
for 1 h at DOC and then tert-butyl carbazate (1.62 g. 12.3
mrol) in 10 ml dichloromethane was added dropwise. Stirring
was continued for 2 h at room temperature. The reaction
mixture was diluted with ethyl acetate (150 mIl and washed
with saturated NaHC01 (2 X 50 ml), 0.1 N HCl (2 x 50 ml),
saturated NaCl (2 x 50 ml), H20 (50 ml), then dried (M3S0~) and
evaporated to give crude protected hydrazide. The product was
purified by flash chromatography with two solvent mixtures:
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first 1:2 and then 2:3 acetone/hexane to yield 2.44 9 (60%) of
13: mp 182-1B4OC; IR (KBr) 3545 and 3329 (NH), 3093 (Ar), 2991
(alkane) and 1710 (C==O) cm-1i lH tl'o1R (Acetone-d.:;) 09,60 (s,
lH, NH), 8.02 and 7.53 (two d, 4H, J=8.6 Hz, para-substituted
phenyl group), 7.07 (5, 2H, rnaleimido-Hl, 2.99 (6, IH, NH) I
1.45 (6, 9H, 3 x 0i31; 1Je lIJv1R (Acetone-~) 3 169.06 (2),
165.63,155.47,134.79,134.34 (2), 131.38, 127.68 (2), 125.59
(2), 79.50, 27.30 (3); MS, role: 331 (W). Anal. Caled for
C16HI'INJ~: C, 57.97; H, 5.17; N, 12.69. Found: C, 58.06; H,
5.14; N, 12.73.
4-MaleiJnidobenzohydrazide trifluoroacetate salt (15)
The powder of 13 (SOD rrg, 1.51 lfIOCll) was dissolved in
ice-cold trifluoroacetic acid (5 mll and stirred for 30 min in
an ice-bath. The trifluoroacetic acid was removed lU1der
vacuum at RT to give compound 15 quantitively: mp 142-144OCi
IR (KBr) 3500-2500 (~H), 3277 (NH), 3111 (Ar), 2901 and 2720
(alkane) and 1710 (C=O) cn-r'; lH NJvlR (CMSO-~) a 11.62 (bs, IH,
N!lNHj' CF.lO:1-), 8.63 (bs, 3H, NH/), 8.0l and 7.56 (two d, 4H,
J=8.5 Hz, para-substituted phenyl group), 7.24 (s, 2H,
maleimido-H)i uCNIvlR ([MSO-~) &169.60 (2), 165.43, 135.47,
134.97 (2), 129.38, 128.38 {2}, 126.46 (2); MS, m/e: 200 (W-
145). Anal. calcd for CUHI8NJOsFl: C, 44.17; H, 5.14; N, 11.89.
FOWld: C, 44.16; H, 5.06i N, 11.93.
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N- (4-Maleimidobenzoyll -6-aminocaproic acid (tert-butyloxy-
carbonyl) hydrazide (14)
CompoW1d 14 was prepared directly from 4 by coupling to
tert-butyl carbazate. The powder of 4 (1.05 g, 3.18 mHol) was
suspended in 30 ro1 dichloromethane and cooled to o"e before
the addition of TEA. (0.49 ml, 3.52 mroll and isobutyl
chloroformate (0.45 ml, 3.44 mnoll. The mixture was stirred
for Ih at ace and then tert-butyl carbazate (0.42 g, 3.18
nmol) in 10 ml dichloromethane was added dropwise. Stirring
was continued for 2 h at room temperature _ The reaction
mixture was diluted with ethyl acetate (100 101) and washed
with saturated NaHCOJ (2 x 50 mIl I 0.1 N Hel (2 x 50 1011,
saturated NaCl (2 x 50 ml) , H20 (50 mIl, then dried (MgS0.,) and
evaporated to give crude protected hydrazide. The product was
purified by flash chrOlT'atography with two solvent mixtures:
first 2:3 and then ~:1 acetone/hexane to yield 1.01 9 (72%) of
14: mp 137 - 139"C; IR (KBr) 3310 (NH), 3082 (Ar), 2978 and
2934 (alkane) and ~707 (C=O) cm-1i lH NMR (Acetone-~.l 08.80
(t" 1H, NH), 8.00 and 7.48 (two d, 4H, J=8. 7 Hz, para~
substituted phenyl group), 7.73 (t, 1H, J=4. 7 Hz, N!:!.CH~), 7.07
(s, 2H, rraleimido-H), 3.41 (q apparent, 2H, J=6.9 Hz, a~lN),
2.88 (s, 1H, NH), 2.21 (t, 2H, J=7.3 Hz, Qi~CO), 1.64 (m, 1H,
2 x 0I2), 1.44 (m, 2H, 0I2 , superimposed on '"Bu group), 1.41
{s, 9H, 3 xCH))i lJC NMR (Acetone-dr,) 0172.74, 170.22 (2),
166.47,156.45,135.39 (2), 135.19, 134.94, 128.45 (2), 126.65
7.
(2), 80.17, 40.24, 34.15, 29.91 (superimposed on acetone
peak). 28.36 (3), 27.08, 25.64; MS, m/e: 200 (M'-244), Anal.
calcd for C22H2SNP6: C, 59.43; H, 6.35; N, 12.61. Found: C,
59.48; H, 6.31; N, 12.58.
N- (4-MaleimidobenzoyJ) -6-aminocaprohydrazide trifluoroacetate
salt (MBCH) (16)
Compound 14 (500 mg, 1.12 l11'OC>l) was dissolved in ice-cold
trifluoroacetic acid (5 ml) and stirred for 30 min in an ic.:e-
bath. The trifluoroacetic acid was rerroved under vacuum at RT
to give compound 16 quantitatively as oily yellowish gum: IR
(KBr) 3500-2500 (C'O:.!H), 3107 (Ar) I 2944 (alkane) and 1717
(C=O) em"; lH n-m. (CMSO-4;l a 10.91 (bs , IH, NHNH/CFJ C02") J 9.4
(bs , 3H, NHJ ') , 8.57 {t , IH, J::S.5 Hz, Q{2N!il, 7.95 and 7.45
(two ct, 4H, J=8.S Hz, para-substituted phenyl group) I 7.22 (s,
2H, maleimido-H), ),28 (qapparent, 2H, J=6.6 Hz, Q{2N) , 2.25
(t, 2H, J=7.3 Hz, Of2COl, 1.57 (m, 4H, 2 x 012 ), 1.34 (m, 2H,
Q-{2); llC NMR (I:MSO-d.J) a 171.79, 169.75 (2). 165.51, 134.86
(2), 133.95, 133.78, 127.82 (2), 126.22 (2), 40.22
(superimposed by DMSO), 32.73, 28.84, 26.01, 24.49; MS, m/e:
69 (M'-389). Anal. Calcd for Cl~21N406Fl: C, 49.77; H, 4.62; N,
12.23. Found: C, 49.80; H, 4.57; N, 12.27.
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Synthesis of 13- [(4-maleimidobenzoyl) hydrazone] doxorubicin
(MBH-Dox) (17)
[)ox'Hel (20.58 mg, 0.036 rrrrol) and 4-maleilllido-
benzohydrazide trifluoroacetate salt (15) (41.28 mg, 0.120
rrmol) were dissolved in 5 ml methanol with the addition of 3
~l TFA. '!'he mixture, protected from light, was sti:t'red at RT
for 1 day. The metha1i.olic solution was concentrated to 1 ml
under nitrogen at RT. Acetonitrile (4 ml) was added for
precipitation and the suspension was allowed to stand at 4''C
for 1 day. The red precipitate was isolated by centrifugation
and then dried under vacuum to 9ive crude product, 20. 2 mJ
(72%). The remaining solution was concentrated down to 0.5 1111
and then acetonitrile (4 mIl was added fOl" precipitation. The
crude product was isolated by the same procedure as above and
gave 6.5 Tt'9 (23%). The crude product (6.5 rrg) was further
purified by 'ILC, using CHC_J/MeOH (85:15) and then scraped
out. The silica gel containing the desired product was washed
with QlC1J /MeQH (30 ml, 85:15) and filtered. After
evaporating the solvent from the filtrate, the residue was
dissolved in 2 ml MeOH and then transfered to a test tube.
The methanolic solution was concentrated down to 0.5 ml and
acetonitrile (3 ml) was added. Precipitation was induced by
drying the solution to 1 ml W1der nitrogen. The suspension
was allowed to stand at 40C for 1 days. The red precipitate
was isolated by centrifugation and dried under vacuum to give
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4.8 Il'g (75%) of 17: 1H Ni'1R (r:M30-~) a 14.07 {5, 1H, OH-11) ,
13.35 (bs, 1H, 00-6), 11.86 (6, 1H, CONHN) I 7.93 - 7.64 (ro,
9H, NH, NH)', H-l, H-2, H-3 phenylene: H-2, H-6), 7.50 (d, 2H,
J,=8.4 Hz, phenylene: H-3, H-5) I 7.22 (6, 2H, maleimido-H) I
5,49 (d, 1H, J", 5.6 Hz, H-l'), 5.31 (bs , 1H, H-7), 5.12 (bs,
lH, HO·14), 4.63 (s, 2H, 0l2-14), 4.56 (d, 1H, J:S.74 Hz, H-
5'1, 3.98 (s, 3H, OCHll. 3.55 (bs, 1H, H-4'), 1.18 (d, 3H,
J" ..... =5.85 Hz, CHJ -6').
Synthesis of 13- [N- (4-maleimidobenzoyl) -6-aminocaproyl
hydrazono] doxorubicin (MBCH-Dox) (18)
Dox' HeI (20.34 rrg, 0.035 nrool) and N- (4-maleimido-
benzoyl) -6-aminocaprohydrazide trifluoroacetate salt (16)
(53.65 lTg, 0.117 ll'V'OOl, assuming 100% yield obtained from 52 rrg
of 16) were dissolved in 5 ml methanol with the addition of 3
/il TFA. The mixture, protected from light, was stirred at RT
for 24 h. The methanolic solution was concentrated to 0.5 ml
under vacuum at RT. Acetonitrile (4 ml) was added for
precipitation and the suspension was allowed to stand at 40C
for 24 h. The red precipitate was isolated by centrifugation
and dried under vacuum to give 28.2 fT9 (90%) of 18; 1H NMR
O:X'-1S0-q,) 614.10 (s, 1H, OH-11) , 13.32 (s, 1H, OH-6) , 10.34
(s, 1H, CONliN), 8.46 (t, IH, J=5.3Hz, NH), 7.90 (m, 7H, NHJ ',
H-l, H-2, phenylene: H-2, H-6), 7.60 (dd, 1H, J=4.3 and 2.6
Hz, H-3), 7.42 (d, 2H, J=8.4 Hz, phenylene: H-3, H-5), 7.21
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(s, 2H, maleimido-Hl, 5.49 (bs, 1H, H-1'), 5.:)1 (00, 1H, H-7),
4.95 (t, lH, J=6.4 Hz, HO-14), 4.42 (s, 2H, 012 -14),4.04 (q,
1H, J=6.7Hz, H-5'), 3.95 (s, 3H, OCHJ ), 1.1B (d, 3H, J ::6.4
Hz, Ql)-6').
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CHAPTER III : SYNrHESIS AND BIOLOGICAL EVALUATION
OF IMMUNOCONJUGATES
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III 1.0 INTRODUCTION
The heterobiftUlctional spacers, MBA. (3), MBCA. (4), MEllA
(5), MBH (15) and MBCH (16), were synthesized and coupled to
Dox as described in chapter II. The stability and reactivity
of the new spacers were determined spectrophotometrically to
optimize the conjugation conditions. Monoclonal anti-CEA
antiOOdies (11-285-14) were thiolated by 2-iminothiolane (2-
IT) and then allowed to react with maleimide groups of Dox
derivatives, 7, 8, 9, 15 and 16 at pH 7.0, giving conjugates,
19, 20, 21, 22 and 23 respectively. The binding ,:(;tivity of
11-285-14 to CEA after thiolation and conjugation was assessed
by enzyme-linked iTl1lTLlI1Osorbent assay (ELISA). The Dox-
maleimido conjugates were analyzed and characterized by using
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE:). The efficacy of these conjugates was determined
in vi tro with human turror cell lines using a colorimetric
assay with 3-··j, S-dimethylthiazol-2, S-diphenyl tetrazolium
bromide (MIT).
III 2.0 MATERIALS Ii: METHODS
III 2.1 pH Optimization of Maleimide Reactions
Crossing-linking reagents containing maleimide have been
widely used for conjugation reactions. The efficiency of
conjugation has been shown to be pH dependent (Knight, 1979).
To develop the conjugation conditions, the rate at which the
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maleimido derivatives hydrclyze to maleamic acids and the rate
at which the maleimido derivatives l:eact with DL-cysteine were
characterized at different pHs by spectrophotometer.
Materials
1. Phosphate Buffer (0.1 M, pH 8.0, 1 rrM EDTA)
Monobasic sodium phosphate-Hp (SOH, Toronto, Ont)
0.73 :f
Anhydrous dibasic sodium phosphate (SOH) 13.'14 9
EDTA (SOH) 0.29 9
Distilled water 1 L
Phosphate Buffer (0.1 M, pH 7.0,1 rrM EDTA)
Monobasic sodium phosphate-H20 5.38 9
Anhydrous dihasie sodium phosphate 8.66 9
EDTA 0.29 9
Distilled water 1 L
Phosphate Buffer (0.1 M, pH 6.5, 1 rrM EDTA)
Monobasic flodium phosphate-H20 9.45 9
Anhydrous dihasie sodium phosphate 4.47 9
EDTA 0.29 9
Distilled water 1 L
2. MBA, MBCA and MBUA
3. DL-Cysteine (Aldrich Chern. Co., Milw., WI)
4. N, N-D:>.ethylformamide ([MF) (Mallinckrodt IIlC., Pointe-
Claire, Quebec)
5. Spectrophotometer (Becknan m1'-70) (Beckman Instruments
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Inc.; Fullerton, CAl connected. to printer (Panasonic KX-
PI09li)
Methods
III 2.1.1 Model Base-catalyzed Hydrolysis of Maleimide
Modification of methods from Knight (1979)
1. 1 1l\'JI male imido derivatives (MBA, MBCA and MBUA) in I:MF
were prepared from 10 rrM stock solution.
10.5 lTJJ MBA/4.835 ml DMF (10 oM)
)0.7 mg MBCA/9. 290 rol I:MF (10 flt.1)
41.3 rrg MBUA/IO.313 ml eMF (10 rrM)
2. 300 iiI of 1 rrfJl rraleimide (MBA, MBCA or MEDAl in J:r.1F was
incubated with 2.7 ml of 0.1 M phosphate buffer (PS), pH
6.5, 7.0 and 8.0, containing 1 TIM EDTA , for 1.5 h at room
temperature (RT).
). Hydrolysis of maleimide to maleamic acid was followed
spectrophotorretrically from 240 to 300 run.
III 2.1.2 Model COnjugation of DL-Cysteine to Maleimide
1. 300 J11 of 1 rrM maleimi.de (MBA, MBCA or MElIA) in DMF was
incubated with 2.7 ml of 0.5 rrM DL-cysteine in 0.1 M
phosphate buffer, pH 6.5 and 7.0, containing 1 oM EDTA,
for 1.5 h at RT.
2. The condensation reaction between thiol and rraleimide was
followed spectrophotometrically between 240 and 300 nm.
120
III 2.2 Generation of Anti-CEA Monoclonal Antibodies
The mouse hybridoma. (11-285-14) which secretes anti-CEA
monoclonal antibody was already established in the Oncol03Y
Research Laboratory. 11-285-14 is an IgGl MAb and has been
extensively characterized and evaluated for in vitro and in
vivo targeting (Casson et aI, 1985) and was supplied to me
after preliminary purification of ascitic fluid on a prote:in-A
affinity colu!lU1 (Ford et aI, 1987a).
III 2.3 Thiolation of Anti-CEA Monoclonal Antibodies
There are several approaches by which a free thiol can be
linked to the amino group of antiJ:xxiy. 2-Iminothiolane was
chosen because it is quite water soluble, it reacts rapidly
with amino groups at pH 7 or a little above, it does not
require an activation step to release the thiol group, and it
preserves the cationic charges of the rrodified amino groups.
The content of thiol was measured by 5,5' -Dithiobis- (2-
nitrobenzoic acid) (D'INB) (Riddles, Blakeley & Zerner, 1979).
Materials
1. Phosphate Buffer (0.1 M, pH B.O, 1 rrM EDTA)
Phosphate Buffer (0.1 M, pH 7.27, 1 ntJI EDTA)
Monobasic sodium phosphate-Hp 3.45 g
Anhydrous dibasic sodium phosphate 10.65 9
EDTA 0.29 g
Distilled water 1 L
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2. 2-Iminothiolane-HCl (2-IT) (4.4 rrM) (Aldrich Olen. Co.,
Milw.• WI)
3.17 rrg 2-IT in 5.231 m1 PB (O.l M, pH 8.0, 1 lTM
EDTAI
). 5,5' -Dithiobis- (2-nitrobenzoic acid) (DTNB) (1 rrM)
(Sigma, St, Louis, MJ)
3.96 rrg D'INB in 10 ml PB (0.1 M, pH 7.0, 1 rrM EDTA)
4. Anti-CEA MAb (11-285-14)
1.32 rrg/ml in PB (0.1 M, pH 8.0, 1 !'I'M EDTA)
7. Sephadex G-25 (Pharmacia Fine Chemicals, Upsala, Sweden)
8. Gel filtration column (Pharmacia Fine Chemicals I
9. Dual Path Monitor 1.N-2 (Pharnacia Fine Olemicals)
10. SpectrophotCllreter (Beckman Off -60) and printer (Epson LX-
810)
Method
totxlification of the rrethod of King, Li & Kochcumi.an
(1978) .
1. 0.5 ml of 1.32 lT9/ml 11-285-14 in PB (O.l M, pH B.O, 1 rrM
EDTA) was treated with 2-IT from 0 to 400 Jl1 and the sarre
PB was added to make up the final volume to 0.54 mI.
2. The mixtures containing 11-285-14 and 2-IT were gently
shaken at Rl' for 2 h.
3. Then, all mixtures were kept frozen or at 4"C W1til the
gel filtration column was ready.
4. 'The thiolated MAbs were freed of excess 2-IT by passage
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through a Sephadex G-25 col'lmn equilibrated with PB (O.1
M, pH 7.27. 1 rrM EDTA) and collected as a single fraction
m:mitored by W-abso:rption. This was set up at RT, but
the PE was kept in an ice-bath and flushed with nitrogen.
5. The protein content was assessed spectrophotometrically
at 280 run using a molar extinction coefficient of 214600
6. 100 pI DTNB was added to 900 ,:11 thiolated 11-285-1tI.
The reaction was incubated for 30 min at RT. The thiol
content was assessed spectrophotometrici'll1y at 412 om
using a molar extinction coefficient of 14150 M I em I.
7. The molar ratio of thiols/MAb was calculated from the
following : OOU2/0D2BO
8. A linear n:~ression curve of SHIMA£> (abscissa) with 2-
IT/MAb (ordinate) was constructed.
III 2.4 Production of Dox-anti-CEA Conjugates
D:lx-maleimido derivatives were used for conjugation to
anti-CEA MAbs that were thiolated with 2-IT. The conjugation
reaction was performed under mild conditions at pH 7.0 at RT.
Materials
1. Phosphate Buffered Saline {PBS} (0.1 M, pH 7.0, 0.9%
NaC!, 1 rrM EDTA)
Monobasic sodium phosphate-H20 5.38 g
Anhydrous dibasic sodium phosphate 8.66 9
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Scxlium Ot!oride (BDH) 9 9
Em'A 0.29 9
Distilled water 1 L
Phosphate Buffer (0.1 M, pH 7.27, 1 rrM EDTA)
Phosphate Buffered Saline (PBS) (0.15 M, pH 7.2) prepared.
frem PBS tablets (Oxoid, Urlipath Ltd., England),
dissolved water as per manufacturer's instructions.
2. 2-IT (0.1 M)
3. DTNB (1 rrM)
4. lID'
5. Anti-CEA MAb (11-285-14)
1.44 - 1.70 mg'/ml in PB (0.1 M, pH 8.0. 1 rrM EIYI'A)
6. Doxorubicin-maleimido derivatives (7, 8, 9, 17 and 18)
7. Sephadex G-25 (Pharmacia Fine Olemicals)
8. Gel filtration colurlU'l (1.6 x 30 em) (Pharmacia Fine
O1emieals)
9. Dual Path Monitor tN-2 (Phanracia Fine Chemicals)
10. Dialysis tubing (rrole~ar weight cutoff 12000-14000)
(Spectrum Medical Industries Inc., Houston, Texas)
11. Amicon ultrafiltration cell fitted with an Amicon RJlIO
ultrafilter (TTOlecular weight cutoff 10000) (Amicon
Corp., Lexington, Mass)
12, Millex eN filter (0.22 IJml (low protein binding)
(Millipore Products Division, Bedford, W\)
13. Spectrophotareter (Beckman [)(f9-60) and printer {Epson LX-
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810)
Methods
III2.4.1 Tbiolation of Anti-CEA Ml\bs
1. 15 - 20 m1 of 1.48 or 1.70 rrs!mlll-285-14 in PB (0.1 M,
pH 8.0, IITM Er1I'A) were treated with 0.1 M 2-IT from 158
- 197 Itl to make the rrolar ratio of 11-285-14 to 2-IT
1:100.
2. '!he mixture containing 11-285-14 and 2-IT was gently
shaken at RT for 2 brs.
3. lhen. the mixture was kept frozen or at 4"C Wltil the gel
filtration colUllUl was ready.
4. 3 ml of thiolated MAbs was freed of excess 2- IT by
passage through a 1.6 x 30 em Sephadex G-25 column
equilibrated with PBS (0.1 M, pH 7.0, 0.9% NaCl. 1 rrM
EDTAI and collected as a single fraction rronitored by IN-
absorption. This was set up at RT. wt the PBS was kept
in an ice-bath and flushed with nitrogen. 'I11e same
prcx:edure was repeated for the remaining MAbs-2-11'
mixture and the fractions collected .....ere r:ombined
together.
5. The thiolated 11-285-14 was concentrated down to 14 . 15
ml by ultrafiltration in an Amicon ultrafiltration cell
fitted with an Amicon F'-110 ultrafilter (molecular weight
cutoff 10000) (Andeon Corp.) .
6. 20 - 30 pI D'INB was added to 100 p.l 11-285-14 aid PB (0.1
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M, pH 7.27, 1 rrM EDTA) was added to rrake a final volume
of 1 ml. 'The reaction was incubated for 30 min at RT.
7. The ratio of thiol/n-285-14 was determined as described
before.
III 2.4.2 Molar Extinction Coefficient of Dox Derivatives
1. 8.75 - 10 III of 10 rrM Dox 3'-N-amide derivatives (1.71 ng
MBA-Dox in 230 III DMF, 1.61 rrg MBCA-Dox in 188 III eMF and
2.06 mg MBUA-Dox .in 222 pI DMF), 10 III of 13.04 rrM Dox-
MBH (11.07 rrg in 1.070 ml eMF) and 20 Joll of 6.24 rrM Dox-
MBaI (7.20 rrg in 1.273 m1 DMF) were diluted to 1000 p.I by
LW'.
2. 500 III of the above solutions were taken out and further
diluted to 1aaO Joll with [XIfF. The double dilution
procedure repeated to get five different
concentrations of each Dox derivative.
3. The absorbance of each Dox derivative at different
concentrations was assessed spectrophotornetrically at 280
and 495 run.
4. The rrolar extincti~i'! coefficient was obtained from a
linear regression curve which was constructed from
absorbance (ordinate) against Dox derivative
concentrations (abscissa).
III 2.4.3 Maleimide Conjugation: Method 1
1. 50 J.ll of MBA-Dox (1.25 ffi3 in 302 J.ll CMF, 5.57 rrM), MBCA-
Dox (3.13 ng in 661 J.ll I:MF, 5.53 rrM) or MBUA-Dox (2.04 rrg
12.
in 435 pI r:t-1F', 4.80 lIM) was diluted to SOD pI with J:lIo1F.
2. 500 JlI of the above [)ox derivative solution was added
within 10 min to 2.5 m1 of 11-285-14 (1.44 or 1.67 mg/ml
containing 6.26, 6.55 or 7.14 thiols/MAb in PRS, pH 7.0,
lrrM EDTA, 0.9\ NaCl) at RT. Vigoroos stirring was
continued only for about 5 5 after each addition of 00:<
derivative. The reaction r.dxture was incubated in the
dark for an additional 1 h 20 min period and stirred
(every 10 min) .
3. The conjugate was then separated from unconjugated COx
derivative by passage through a 1.6 x 30 an Sephadex G-25
column equilibrated with PBS (0.15 M, pH 7.2 prepared
from PBS tablets) and collected as a single fraction
m:mi.tored by W-absorption fran a W IOOnitor.
4. COnjugate fractions concentrated down by
ultrafiltration in an Amicon ultrafiltration cell fitted
with an Amicon A-UO ultrafilter l"'Olecular weight cutoff
10000) .
5. The conjugate solution was transferred to dialysis tubing
and dialyzed 2 x 8 h in PBS, pH 7.4 (iLl (prepared from
tablets) .
6. The conjugates were sterilized through Millex GIl filters
(0.22 Jjml (low protein binding) (Millipore, Bedford, MA)
7. The absorbances of conjugates were determined at 280 run
and 495 run to estimate protein and drug concentrations
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respectively.
III2.4.4 Maleimide Conjugation: Methoci 2
1. 25 III of MBH-Dox (11.07 rrg in 1.07 ml DMF, 13.04 rrM)
diluted to 50 Jll with I:MF or 50 /11 MBOI-Dox (7.20 rrg in
1.273 ml CMF I 6.24 nM) was added in 10 Jl1 aliquots every
5 min to 3.0 ml of 11-285-14 (1.56 or 1.62 rrg/ml
containing 6.55 or 6.59 thiols/MAb in PBS, pH 7.0, IfltJl
EnTA, 0.9% NaCl) at RT. Vigorous stirring was continued
only for about 5 s after each addition of Dox derivative.
The reaction mixture was incubated in the dark for an
additional 1 h 10 min period and occasionally stirred
(every 10 min) .
2. The rest of the procedure was the same as section III
2.4.2 (e), steps 3 to 7.
III 2.5 Enzyme Linked Imrm.1nosorbent Assay (ELISA)
An anti·CEA. semiautomated ELISA using micro cuvett.es
(Woodhouse, F'ord & Ne'.lJlTlaI1, 1982; Ford et aI, 1987a) was
rrodified to 96 well microtitre plates (Reddy and Ford, 1993).
The microtitre plates are a convenient and rapid method for
testing large numbers of samples.
Materials
1. Microtitre ELISA plates (101 Biomedicals Inc., Horsham,
PAl
2. Nkhiryo digital multichannel pipette and disIXJsable tips
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{Fisher Scientific Co., Toronto, Ont}
3. Buffer for ELISA
carbonate Bicarbonate Buffer (0.1 r-l, pH 9.2)
Sodium carbonate (Fisher) 1.59 9
Sodium Bicarbonate (Sigma) 2.93 9
Distilled water 1 L
1% ESA caroonate Buffer (pH 9.2)
BSA (Sigma) Ig
carbonate Buffer (0.1 M, pH 9.2) 100 ml
Citrate Phosphate Buffer (0.1 M, pH 4.0)
Citric Acid (BOH) 9.06 9
Dibasic sodium Phosphate 8.16 9
Distilled water 1. L
1% BSA-PBS-Tween Diluent
BSA 19
PBS (pH 7.2) 100 ml
Tween 20 (BOH) 100 111
Saline Tween
Sodium Chloride (O.15M) 8.769
Tween {O.l%l 1 ml
Distilled water 1. L
4. 2,2'-azino-di- ()-ethyl-benzthia2oline sulphonic acid)
(ABTS) (Sigma, St.Louis, MO). Stock: 27.8 ng/ml in
distilled water and stored as lOa pol aliquots at -20''C
100 III stock
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12.5 ml citrate phosphate buffer
1 III hydrogen peroxide (30\: BDH)
5. Peroxidase conjugated rabbit anti-mouse inmmoglobulL"1.s
(Dako. Denmark)
6. Bio-Tek EL310 EIA plate reader (Mandel Scientific,
Rockwood, Ont)
7. CEA (supplied by Oncology Research Laboratory) purified
as published (Ford et aI, 1987a) in carbonate bicarbonate
buffer (O.1M, pH 9.2)
8. 11··285-14 anti-CEA rronoclonal antil:x::dy (positive control)
9. 1% BSA-PBS-'IWeen (negative controll
Method
1. ELISA plates were coated with 100 pI per well of 5 J..I9
ml- l CEA in carbonate buffer (pH 9.2) and incubated for
3 hours at 370C followed by storage in a humidified box
at 4"C overnight.
2. The coating solution was pipetted out and stored at -20"C
for later use.
3. The plate was washed six times with NaCl-Tween solution
using a wash bottle, ensuring that each well was filled.
4. 200 .pl of 1% 88A in carlxmate buffer was added to each
well, as the blocking solution.
S. The plate was then incub.."'\ted at 370(: for 1 hour.
6. The plate was washed as before (step #3) .
7. The test supernatants were prepared at appropriate
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dilutions in l%BSA-PBS-'IWeen and added, 100 ~1 per \oJell.
The controls used for anti-CEA assays were: positive
control, 11-285-14 MAb 2.5 Ji.g/rnl; negative control, 1%
ESA-PBS-Tween instead of test supernatants. The test was
performed in quadruplicate for each dilution.
S. The plate was then incubated at 370C for 3 hours.
9. This was followed by x 6 washes as before (step ff3).
-~o. Rabbit anti-rouse inmunoglobulines - HRP conjugate (RAM)
1:1000 dilution in 1% BSA PBS-Tween was added, 100 ~1 per
well.
11. The plate was then incubated at 370C for 3 hours.
12. The plate was washed x 0 as before (step #3).
13. Freshly prepared ABTS substrate, 100 III was added per:
well and the plate was read after 1 hour at RT at 405 om
single wavelength, by a BioTek EL 310 8IA plate reader
(Mandel Scientific, Rockwood. Ontario)
III 2.6 ELISA for Thiolated Anti-CEA Antibody
Materials
1. The materials outlined above, section III 2.5.1
2. Thiolated 1l~285-14 in PB (0.1 M, pH 7.0, 1 rrM EDTA).
Method
The assay outlined aOOve, section III 2.5.2, was used to
test antibody activity of t~liolated 11-285-14 (3.35 - 13.50
SH/MAbl, with 11-285-14 as a control. concentrations tested
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were 1 x ~o-s - 10000 ng/ml and tests were performed in
quadruplicate. Standard curves of absorbance {abscissa! with
antibody concentration (ordinate) were constructed.
III 2.7 ELISA for Testing Conjugates
Materials
:i.. The materials outlined above, section III 2.5.1
2. Dox-11-28S-14 conjugates in PBS (pH 7.4, PBS tablet).
Method
The assay outlined aOOve, section III 2.5.2, was used to
test antiJ::xxiy ar.tivity of doxorubicin conjugated 11-285-14,
with 11-285-14 as a control. Concentrations tested were 1 x
10.5 - 10000 ng/ml and tests were performed in quadruplicate_
Standard curves of absorbance (abscissa) with antibody
concentration (ordinate) were const:ructed.
III 2.8 Human Tumor Cell Culture
Human turror cell lines utilized in this study were
already established in culture in the Oncology Research
Laboratory (Ford et aI, 1987b). 'They were obtained initially
from the American Type 011ture Collection, Maryland, USA.
III 2.9 Microcytostasis Assay
Cherrosensitivity of cell lines to doxorubicin,
doxorubicin derivatives or the rronoclonal antiOOdy-doxorubicin
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conjugates was assessed with a colorimetric assay that uses
the ability of viable cells to reduce a soluble tetrazolium
salt. 3-4. S··dimethylthiazol-2, 5-diphenyl-tetrazolium brcrni.de
(MIT), into a.T1 insoluble fomazan precipitate (Demzot & lang,
1986) with rrodifications (Ford. Richardson & Tsaltas, 1989).
The colorirretric assay has the advantages of being safer, less
costly and simpler than the radiometric assays.
Materials
1. Human 'l\.lmor Cell Line used, with source (obtained from
the American Type C'ulture Collection, Maryland, USA)
LS174T
COL0320I:fJl
S<lll=
Ad.enocarcinoma, colon
Adenocarcinana, colon
2. Media required for cell Culture, including supplements
(all materials supplied by Flow labs.)
~
-
SUpplements
lS174T RRU-1640 50 ml fetal calf serum (8.8.)
(500 ml) 6 ml glutamine
12 ml penicillin-streptomycin
COLD320D-1 MinilTUffi 50 ml fetal calf serum (8.8\)
essential 6 ml glutamine
medium 6 ml non-essential amino acids
(500 mll 12 ml penicillin-streptomycin
3. Cell suspension 100; cells/ml in appropriate medium
following trypsinization
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4. Microtitre plates, 96 wells (Flow Lab. Inc. I McLean,
Vi.rginia)
5. Medium-sterile
6. MIT (Sigma) in PBS (stock: Srrg(mll
7. DMSO (Sigma)
8. Bio-Tek EL310 EIA plate reader (Mandel Scientific)
9. Doxorubicin (Adria LaOOratories Inc., Columbus, Ohio)
specific doxorubicin concentrations varied in different
batches
Stock solution of Dox in 0.9% NaCl
10. Doxorubicin Tl\3.1eimido derivatives
Specific doxorubicin derivative concentrations varied in
different hatches
Stock solution of Dox 3' -N-amide derivatives in MeDH
Stock solution of Dox C-13 hydrazone derivatives in 0.9%
NaCl
11. 11-285-14 Doxorubicin conjugate
Specific doxo.rubicin concentrations and irnnunoglobulin
concentratiJns varied in different batchLS
Method
EssentitHy as for Ford, Richardson & Tsaltas (1989).
1. Under sterile conditions, 100 pI oi the cell suspension
was dispensed into wells of the microtitre plate, such
that each well contained 104 cells.
2. The plate was incubated for 24 hrs at 370C in a
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humidified atmosphere of 5% carbon dioxide.
3. Under sterile conditions, medium was aspirated by
multiple channel pipette from the wells and doubling
dilutions of drug, drug derivatives (Dox 3' ··N-amide
derivatives added in 5% MeoH) or conjugate were added in
a volume of 100 Jll to each well. The test was performed
in quadruplicate for each dilution, with appropriate
control wells that received 100 Jll of medium only. 5%
MeOH of medium in doubling dilutions were performed in
quadnlplicate as control in comparision to the Dox 3' -N-
amide derivative testing. The plate was incubated for 24
hr at 37"C as before.
4. The medium was aspirated in a similar marUler to
previously and each well washed 3 tirres with sterile PBS
(2001.l1) at RT. 100 I.ll of medium was then added to each
well and a 24 hrs recovery period followed.
5. Following removal of the medium by aspiration under
sterile conditions after recovery I 100 Jill: 10 dilution
of MIT stock was added to each well. A 4 hr ~ ncubation
period in the humidified incubator at )7'"'C followed.
6. The medium was aspirated from each well. 100 Jil CMSQ was
added to each well and the plate was agitated on a plate
shaker for 20 min.
7. The plate was read spectrophotometrically at 570 and 630
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8. Results from the plate reader were expressed as follows:
P€::rcentage Cell Survival at Each Dilution
r-tean Absorbance at Each Dilution
x 100
Mean Control Absorbance
9. A dose response curve of percentage cell sw:vival
(ordinate) against drug concentration (abscissa) was
constructed .
III 2.10 SOS-Polyacrylamide Gel Electrophoresis
Gel electrophoresis was performed on a 10% running gel
and 5% stacking gel.
Materials
1. Tris-Cl (O.15M, pH 8,8)
Tris base (Sigma) 18.15 9
adjust to pH 8.8 with 1M Hel
final volume to 100 ml with distilled water
Tris-Cl (D.SM, pH 6.8)
Tris base 3.0 9
adjust to pH 6.8 with 1M Hel
final volume to 50 ml with distilled water
2. Acrylamide : Bisacrylamide (30%T, 2. 67%C)
Acrylamide (Bic-Had, Richmond, ca) 29.2 9
N, N I -Methylene~i8acrylamide (Bio-Radl 0.8 9
Distilled water 100 ml
Filter and store at 40C in the dark (30 days max.)
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3. 10% Sodium dodecyl sulphate (80s) (80H)
4. 10% arruronium persulphate (Bio-Radl
5. N,N,N',N'-Tetramethylethylenediamine (TEMED) (Signa)
6. Sample buEfer
Tris-Cl (O.SM, pH 6.8) 1.0 ml
Glycerol (Sigma) 0.8 ml
10% SDS 1.6 ml
0.05% Brorrophenol Blue 0.2 ml
final volume to 8. a ml vlith distilled water
7. Electrode Buffer (pH 8.3)
Tris base 12 9
Glycine (Sigma) 57.6 9
SOS 4 9
adjust to pH 8.3 with 1M He!
final volume to 4 L with distilled water
8. High rrolecular weight protein standards (Bio-Radl
Method
1. For preparation of separating gel, 13.35 ml of acrylamide
:bis-acrylamide (3ot T, 2.67% C), 10 ml Tris-Cl (105M, pH
8.8), 0.4 ml 10% SDS and 13.5 ml distilled water were
mixed and deaerated tmder vacuum for 15 min. 0.1 ml 10%
arrmc:mium persulphate and 0.02 ml TEMED were added to the
mixture, gently shaken and irrmediately poured into a
vertical slab gel with 1.5 rrm spacer. Distilled lt/ater
was layered on top of the gel to pr€;!vent evaPJration.
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The separating gel was allowed to polymerize overnight.
2. For preparation of stacking gel, 1.3 rol of acrylamide
:bis-acrylamide (30% T, 2.67% C), 2.5 ml Tris-Cl (O.SM,
pH 6.8), 0.1 rol 10% 80s and 4.1 rol distilled water were
mixed and deaerated. under vacuum for 15 min. 0.1 ml 10%
arrrronium persulphate and 0.01 ml TEMED were added to the
mixture irrrnediately before pouring over the separating
gel. A plastic comb was carefully inserted into the
stacking gel to fann the sample wells.
3. 'l'he sample to be analyzed was added to sample buffer
making 6 - 12 Jl.g of antibody/50 III of buffer, 12 119 of
conjugate/50 III of buffer and 4.5 III of protein standa~-dl
50 pI of buffer before applying to the sample wells.
Electrophoresis was carried out at a voltage of 150 V and
constant current of 2S rnA for 16 h at RT. The rolecular
weight of the examined samples was determined from the
protein standard.
III 2.11 Coanaasie Blue Gel Staining
Materials
1. Fixing solution
G1ycerol 250 ml
Methanol 200 ml
Acetic acid 50 ml
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2. Staining solution {O.25\ Coomassie bluel
Coomassie brilliant blue R 250 (Merck. Darmstadt)
1.25 9
Methanol 125 ml
Acetic acid SOml
Distilled water 325 m1
3. Destaining solution
Destain #1 and #2 (40% methanol)
Methanol 200 ml
Acetic acid 50 rol
Distilled water 250 rol
Defitain #3 (30\ methanol)
Methanol 150 ml
Acetic acid 50 ml
Distilled water 300 ml
Destain #4 (10\ methanol)
Methanol 50 ml
Acet ic ..lcid 50 ml
Distilled water 400 ml
Method
'!he gel was soaked in fixing solution for '1 hrs and then
in staining solution ovenlight. The gel was washed in
destaining solution, 2 hrs in destain #1 and #2, 6 hrs in
destain #3 and overnight in destain #4, with gentle shaking.
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III 3.0 RESULTS
III 3.1 pH Optimization of Maleimide Reactions
The pH dependence of the coupling reactions between
rraleimide and thiol were investigated spectrophotometrically
by addition of MBA (3), MBCA (4) and MBUA (5) to cysteine
thiol at different pHS. The base-catalyzed hydrolysis of
male imide to maleamic acid was also investigated by incubation
of MBA, MBCA and MElIA at different pHs. The coupling and
hydrolysis reactions are sUlTfTBrized in Figure 9.
Figures 10, 13 and 16 show the absorption spectra
recorded during coupling reactions. Tables 2 to 4 and Figures
12A, 15A and lBA illustrate results for the coupling
reactions.
For the linkers, MBA, MBCA and MBUA, the rate of
coupling, cysteine-to-lI1D.leimide condensation, is slower at pH
6.5 and rapid at pH 7.0 (Figures 12A, 15A and l8A). Both MBA.
and MBlIA show higher clu"orrophoric changes at pH 7.0 than at pH
6.5 (Figures 12A and 18A) , indicating that rrore 1l'aleimide
reacts with cysteine thiol at pH 7.0 than at pH 6.5. MBCA
shows virtually the same chrorrophoric changes at pH 7.0 and
6 . 5 (Fig1\re 15A).
Figures 11, 14 and 17 show the absorption spectra
recorded during hydrolysis reactions. Tables 2 to 4 and
Figures 128, 158 and 18B illustrate results for base-catalyzed
hydrolysis reactions.
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recorded at 15 min. intervals for l~ h dunng cysteine-
to-MBA. condensation. MBA (100 1lM> was incubated with
excess cysteine (450 1JM) in 0.1 M phosphate buffer at pH
7.0 (Panel A), pH 6.5 (Panel B). The number beside each
line is the incubation time in minutes.
1.2
. ~
c 0.9 ~~j06~'J/:
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Figure 11. Chraoophoric change of the
hydrolysis of MBA. Absorption spectra were
i~l~~t~%rS~~d~ing~~~l~i~f
MBA. MBA. (100 pM) was incubated in 0.1 M
phosphate J:::uffer at pH 8.0 (Panel A), pH 7.0
(Panel Bl and pH 6.5 (Panel C). Th-e number
beside each line is the incubation tirre in
minutes. (Continued on next pagel.
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Table 2. Absorbance change ot MBA at different pHs when undergoing' ba.e-cataly.ed
hy4rolyda an4 conjugation to cy.teine.
Absorbance at 285.5 nm due to Absorbance at 260 lUll due to
Time base-catalyzed hyarolysis ot MBA at conjugation ot cysteine to MBA at
(min) pH 6.5 pH 7.0 pH 8.0 pH 6.5 pH 7.0
0.0254
0.4601
10 0 0 0.1845 0.0425 0.7671
15 0 0 0.3460 0.1382 0.9891
20 0 0 0.4780 0.2374 1.1528
25 0 0 0.5888
'0 0 0 0.6797 0.4110 1.3635
40 0 0.0175 0.8185 0.5568 1.4800
50 0 0.0808 0.9154 0.6831 1.5475
60 0 0.1402 0.9825 0.7887 1.5845
75 0 0.2247 1.0474 0.9168 1.6170
90 0.0104 0.2988 1.0860 1.0215 1. 6332 ~A
A
Time (min)
Figure 12. Optimal condition of coupling
reaction between MBA and thiol. MBA. (100 tAM)
was reacted with cysteine (450 tAM) in 0.1 M
phosphate buffer at pH 7.0(.) and 6.5 (0)
l~~~kA)pho:t~lOgurtt~r~~e~~t.~1i)~Y~~~
Ie) and 6.5 (0).
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recorded at 15 min. intervals for 1~ h during cysteine-to-
MBCA condensation. MBCA (100 pM) was incubated with
excess cysteine (450~) in 0.1 M phosphate buffer at pH
1.0 (Panel A), pH 6.5 (Panel Bl. lbe number beside each
line is the incubation time in minutes.
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Figure 14 . Chromophoric change of the
hydrolysis of MBCA. Absorption spectra were
r~~~t~e%rS~~dd~fn;e~~~d~~~l~~i:i~f
MBCA. MBCA (100 11M) was incubated in 0.1 M
phosphate buffer at pH 8.0 (Panel A), pH 7.0
(Parlel B) and pH 6.5 (Panel C). The number
beside each line is the incubation time in
minutes. (Continued on next page) .
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Table 3. Absorbance chang-e o~ KBCA at di~~.rent pHs wben underqoinq ba.l!Ie-catalysed
hydrolysis and conjuqation to cysteine.
Absorbance at 285.5 nm due to Absorbance at 260 nm due to
Tillie base-cataly:l.:ed hydrolysis of MaCA at conjugation of cysteine to MBCA at
(min) pH 6.5 pH 7,0 pH 8.0 pH 6.5 pH 7.0
0.1.587 0.1.333
0.2857 0.5138
10 0 0 0.281.2 0.4507 0.7635
15 0 0 0.4930 0.5811. 0.9365
20 0 0 0.6630 0.6911. 1.0317
25 0 0 0.7982 0.7860 1.1265
30 0 0 0.9061 0.8694 1,1778
40 0 0.0658 1. 0647 0.9960 1.2332
50 0 0.1635 1.1621 1.0874 1.2610
60 0 0.2550 1.2272 1..1538 1.2745
75 0 0.3771 1.2828 1.2215 1.2832
90 0 0.4877 1. 3130 1.2634 1.291.0 ~~
~
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Pigure 15. Optimal condition of coupling
reaction between MaCA and thiol. MBCA (100 /-1M)
was reacted with cysteine (450 11M) in 0.1 M
phosphate buffer at pH 7. a (e) and 6.5 {OJ
(Panel A). MBCA (100 ~) underwent hydrolysis
1~) 0~dM6~~o(8~te buffer at pH 8.0 (-), 7.0
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Figure 16. Chromophoric change of MBUA reaction with free
thiol. Absorption spectra were repetitively scanned and
recorded at 15 min. intervals for 1U h during cysteine-to-
MBllA condensation. MBUA {100 tiM} was incubated with
excess cysteine (450 t-!M) in 0.1 M phosphate buffer at pH
7.0 (Panel A), pH 6.5 (Panel B). The number beside each
line is the incubation time in minutes.
j::~~[\ A
-~/
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Figure 17. Chranophoric change of the
hydrolysis of MBUA. Absorption spectra were
repetitively scanned and recorded at 15 min.
intervals for 11;< h during the hydrolysis of
MBllA. MBllA (100 IJM) was incubated in 0.1 M
phosphate buffer at pH 8.0 (Panel A). pH 7.0
(Panel B) and pH 6.5 (Panel C). The number
beside each line is the incubation time in
minutes. (Continued on next page) .
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Table 4. Abaor})ance change of MBUA at different pH. "hen undergoing })ue-catalyze4
hydrolylli. and conjugation to CYlltein••
Absorbance at 285 nm due to Absorbance at 260 nm due to
Time base-catalyzed hydrolysis of HBUA at conjugation of cysteine to MBUA at
(tlin) pH 6.5 pH 7.0 pH 8.0 pH 6.5 pH 7.0
0.1718 0.3082
0.0062 0 0 0.3271 0.9868
10 0.0064 0 0.1984 0.4610 1. 3121
15 0.0067 0 0.4398 0.5761 1.4857
20 0.0071 0 0.6082 0.6818 1.5812
25 0.0077 0 0.7270 0.7742 1.6322
30 0.0077 0 0.8121 0.8567 1.6664
40 0.0081 0 0.9187 0.9970 1.6992
50 0.0090 0.0041 0.9760 1.1042 1.7084
60 0.0092 0.0910 1.0067 1.1894 1.7111
75 0.0098 0.2141 1.0305 1.2808 1. 7132
'0 0.0107 0.3158 1.0441 1.3490 1. 7161 ~~
1.8
E .....-.-.-.-.-.--.--.
~1.2-f~
~ 0.6 - ,,o"'Cf A
3 ,.,0°
.0 i)
«f, 0.0-
-----1 -- -----r----~____.
~(l 40 60 80 100
Time (min)
155
0.4 -
1.2
~
~ 0.8
.
o
i
2
<f, 0.0
..-.----.--.
./
_.~
'"
/ -----.i ~.~.
-.-.-.-..-.-.~
r--'---y----,---,
20 40 60 80 '00
Time (min)
Figure 18. Optimal condition of coupling
reaction between MBUA and thiol. MBUA (100 IJM)
was reacted with cysteine (450 pM) in 0.1 M
phosphate buffer at pH 7.0(.) and 6.5 (0)
(Panel A). MBUA (100 J1M) underwent hydrolysis
t~) 0~dM
6
~~o(8~te buffer at pH 8.0 (.) I 7.0
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'!he rate of chromophoric change is rapid at pH 8.0 and
slower at pH 7.0 (Figures 128, 158 and l8B) , indicating that
the rraleimide is unstable and undergoes hydrolysis at alkaline
pH and even at neutral pH. However, at pH 6.5, there is no
chromophoric change, indicating that maleimide is stable in
slightly acidic conditions.
III 3.2 Thiolaticn of 11-285-14
11-285-14 was thiolated by 2-iminothiolane (2-IT) (Figure
19) . The number of trool groups introduced on the MAb is
highly correlated to the amount of 2-IT used (R-sq '" 99.68%,
P < 0.0001) (Figure 20).
The thiolation is a random process. The thial groups may
be added to the amino group of lysine residues anywhere in the
antiOOdy roolecule, including in the antigen binding site. 'Ib
confirm the binding activity of thiolated 11-285-1'1 to CEA, an
antibody ELISA was performed. Figure 21 compares standard
curves obtained for the thiolated 11-285-14 containing 3.35 -
13.5 SH/MAb and non-thiolated 11-285-14, confirming CEA
binding had been retained although there is some reduction in
binding seen after thiolation. The absorbance 0.5 unit and
antibody concentration 12.27 ng/ml from the control curve was
chosen as a reference point and all the points from other
lines under the reference point were plotted out as a linear
regression curve. The binding activity decreases as the
MAb-NH, + ~NH'CI'S 2
pH 8.0
l57
NH ·CI·
II 'MAb-NHC~SH
Figure 19. lhiolaled MAb prepared by treatment
With 2-lminothiolanEl.
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substitution of thiol groups increases (R~sq
=0.0446) (Figure 21, Inset).
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III 3.3 Synthesis of Doxorubicin 11-285-14 Conjugates
The rrolar extinction coefficients of Dox maleimido
derivatives are surmlarized in Table 5. These values were used
for calculating the drug concentration and conjugation ratio.
Synthesis of the irrrnunoconjugates was accomplished by
thiolating 11-285-14 with 2-IT (Figure 19) and reacting the
thiolated 11-285-14 with the Dox maleimido derivatives
{Figures 22 and 23}. The addition of 11-285-ltl containing
free thiols to Dox 3' -N-amide or" Dox C-13 hydrazone
derivatives led to the formation of thioether and amide bonds
or hydrazone bonds between Dox and 11-285-14.
With the 2-IT/MAb molar ratio, 100, 6.62 ± 0 . .12 (S.D.)
thiol groups were attached to MAbs with high protein yield
(84-85%) (data not shown). 1.68 - 2.58 rrolecules o(
drug/rrolecule of NAb (Table 6) W€re achieved when 10
equivalents of Dox maleimido derivatives were added to
thiolated 11-285-14. '!he final protein yields following
conjugation of drug to MAt were 32 - 60% (Table 7). The total
percentage of drug recovery was 3.01 to 7.05 (Table 8). 'lhis
l:esult showed that the whole process of drug incorporation to
MAbs was not efficient. and only a low drug recovery was
obtained.
Table 5. Molar extinction coefficient of Dox derivatives 7, 8, 9, 17 and 18.
Mola.r Extinction Coefficient
compound h.,.. (nm) , t:~ln 'm Solvent
267 16853 12508 12380 DMF
267 16248 11413 13236 DMF
267 16017 11754 13061 DMF
'7 268 26320 18510 12531 DMF
'8 268 16028 12315 13051 DMF
IgG 280 21.4600 PBS
Oox 3'-N-amide derivatives (7, 8 and 9)
Dox C-13 hydrazone derivatives (17 and 18)
'"~
162
~H:1'CI-
MAb-NHC SH +
pH 7.0 !
Go ",0N-R-C 'NH-DOX
° 7,8,9
mt~C-C~HDOX-NH2 = ''OH"0
OCH30 _OHH I
C
H37FJ
1-0 NH2
19,20,21
-Q---
o
---gJ-N~CH,.­
o
---@-l---NH(CH2~O-
~H;CI" °
MAb-NHC S-q ",0
N-R-C
'NH-DOX
°
9,21 : R=
7,19 : R=
8,?0 : R=
Figure 22. Synthesis of Dox i.mmunoconjugatea by reaction of
2-IT thiolated MAbs with Vox 3'-N-amide derivatives.
Condensation of the Dox derivatives with thiolated MAb leads
to formation of thioether ronds with MAb and N-acyl bonds at
the )' -NH2 position of Dox.
~H;"CI'
MAb-NHC SH +
pH 7.0 1
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Go ",0N-R-C'NHN~DOX. HCI
° 17,18
22.23
~H,' CI' °
MAb-NHC S-q ",0
N-R-C'NHN~DOX• Hel
°
DOX' HCI =
17 .22; R=---Q-
o
18,23; R=-W-"~CH,'-
~?l~,~_C~OHOCH'O~HH""0
C", 0
HO N~'HCI
Figure 23. Synthesis of Dax immunoconjugates by reactJ.on of
2-IT thi.olated z.mbs with COX C-13 hydrazone derivatives.
Condensation of the Dox derivatives with thiolated MAb leads
to farnation of thioether bonds with MAb and C-13 hydrazone
ronda at the C-13 position of Dox.
Table 6. spectrophotometric evaluation ot the Dox-11-285-14 conjugatell
absorbance of absorbance of the conjugation
Conjugate the conjugate drug content protein content drug antibody ratio
number 280nm 495nm 280nm 280run (J,lH) (J,lH) drug/antibody
,. 1.82 0.24 0.24 1.58 19.01 7.38 2 • .58
20 2.10 0.24 0.21 1.89 18.33 8.79 2.09
21 1.13 0.11 0.10 1.04 8.11 4.84 1.68
22 1.41 0.15 0.23 1.18 12.32 5.50 2.24
23 1.16 0.14 0.13 1.02 10.82 0.11 2.27
~
~
Table 7. Protein rocovery atter conjugation reaction
Conjugate protein used protein recovered
number SH/MAb tor coupling (mg) after coupling (mg)
"
7.14 23.38 10.51
20 6.55 23.24 13.84
21 6.26 18.00 5.81
22 6.55 14.58 5.36
23 6.59 14.04 4.65
, yield
4.
'0
"
37
33
m
Table 8. Drug recovery atter coupling and conjugation reaction
conjugate
number
19
percentage recovery of drug after
coupling to linker conjugation reaction
41 H.6l
total percentage
recovery
4.76
21
23
51
56
85
90
12.54
5.38
8.29
7.49
3.01
6.74
~
~
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III 3.4 In Vitro Efficacy
Figures 24 and 25 show the binding activity for
inrnunoconjugates. Dox-MBA and Dox-MBCA. conjugates retained
most of their binding activity compared to Dox-MBUA conjugate.
Dox-MBH and Dox-MBOi conjugates lost some of their binding
activity compared to parent 11-285-14.
Dox-MBA, Dox-MBCA, Dox-MBUA, Dox-MBH and Dox-MBCH
derivatives and their irmmunoconjugates were evaluated in
vitro for cytotoxicity using the MIT assay. The cell lines,
LS174T, which is sensitive to Dax and has high expression of
CEA, and COL0320DM, which is also sensitive to Dex and has low
expression of CEA., (Ford et aI, 1987a; Richardson et aI, 1989)
were used for these assays. The mean absorbances with the
!'itandard deviation for the assays are presented in Tables 9 to
14. The dose-response curves are presented in Figures 26 to
31. Percentage survival of cells is shown along the ordinate
and drug, dnlg derivatives and inmunoconjugaL~s, using a
logarithmic scale, along the abscissa.
All Dox 3' -N-amide derivatives do not show significant
cytotoxic effect on the I.S174T cell line when compad~d to Dox
(Figure 26). The Dox-MBA derivative showed the highest
cytotoxicity and caused 50%' cell smvival at -20 J.lM while Dox-
MB:'A caused 50% cell survival at N40 11M. Dox-MBUA
derronstrated no appreciable cytotoxicity and only shovred 30%
inhibition of cell growth at 40 pM. However, the Dox
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Figure 24. Standard curves ccaparing CEA binding of Dax 3' -N-amide
ixD::Izunocanjugates with parent 11-285-14 by ELISA (Mean :t S.D.) .
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Figure 25. Standard curves ccmparing CEA binding of Dax. C-13 hydrazone
iJrmunoconjugates with parent 11-285-14 by ELISA (Mean ± S.D.).
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Table 9. AbsorbaDce e~'t.iDed froa KTT assay follovibg 24 bour exposure or LS174T calls
to Doz and Doz: 3'-N-aaida derivatives (8taJl,dard Deviation, B.D.)
Doxorubicin Doxorubicin Derivatives
Doxorubicin Hean Percentage Mean Absorbance Percentage of Survival
Concentration Absorbance of Survival MBA MBCA MBUA MBA MBCA M8UA
(J.lM) (S.D.) (S.D.) (s.D. ) (S.D. )
•• 0.059 5.75 0.673 0.461 0.509 42.92 49.60 69.87
(0.006) (0.54) (0.083) ~O.088) (0.029) (5.31) (9.50) (4.0)
2. 0.066 6.49 0.855 1. ~5~' 0.707 47.49 65.79 76.67
(0.032) (0.31) (0.068) (0.140) (0.143) (3.77) (8.74) (15.48)
,. 0.068 6.68 1. 347 1.366 0.896 65.52 71.71 92.6)
(0.006) (0.61) (0.309) (0.221) (0.0,(,)) (15.04) (11.59) (4.47)
5 .• 0.088 8.63 1.641 1.408 1.015 87.96 85.95 105.29
(0.008) (0.83) (0.193) (0.141) (0.072) (10.32) (8.63) (7.51)
2.5 0.193 18.95 1.506 1.553 1.151 95.60 88.31 97.82
(0.015) (1. 44) (0.383) (0.121) (0.071) (24.30) (6.90) (6.07)
~
~
0
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Figure 26. Dose-Response curves for Dox and Dox 3' -N-amide derivatives on cell
line LS174T (mean ± S.D.).
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Table 10. Absorbance obtained fran MI"l' assay following 24 hour expooure of LS114T cells
to Dox and Dox. C-13 hydrazone derivatives (Standard Deviation, S.D.)
Doxorubicin Doxorubicin Derivatives
Doxorubicin Mean Percentage Mean Absorbance Percentage of Survival
Concentration Absorbance of Survival MBH MBOi MBH MBOi
IpM) IS.D.I IS.D.) IS.D.) IS.D.)
40 0.059 5.75 0.061 0.039 5.95 5.82
10.0061 (0.54) (0.008) 10.005) (0.74) (0.821
20 0.066 6.49 0.091 0.045 8.97 6.75
10.0321 10.311 10.015) 10.0071 (1.49) (1.05)
10 0.068 6.68 0.102 0.061 10.05 9.14
(0.006) (0.61) (0.011) (0.013) (1.03) (1.99)
5.0 0.088 8.63 0.177 0.019 17.37 11. 7S
10.0081 10.831 (0.010) (0.003) (0.97) (0.47)
2.5 0.193 18.95 0.308 0.113 30.25 16.83
(0.015) (1.44) (0.036) (0.003) 13.55) 10.37)
1.25 0.354 34.79 0.587 0.194 57.70 28.88
(0.054) (5.21) (0.072) (0.025) (7.10) (3.71)
0.625 0.546 53.64 0.106 0.300 69.39 44.10
(0.053) (5.24) (0.053) (0.014) (5.17) (2.08)
0.313 0.680 66.81 0.832 0.344 81.80 51.31
(0.U4) (10.18) (0.155) (0.036) (15.24) (5.39)
0.156 0.899 88.34 0.999 0.419 98.19 62.57
(0.101) (9.92) (0.060) (0.063) (5.81) (9.46)
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Table 11. lUIsorbance obtained fro. MT'l' ••say folloving 24 hour exposure of COL0320DM
cella to Dox and Dox C-13 hydrazone derivative. (standard Deviation, S.D.)
Doxorubicin Doxorubicin Derivatives
Doxorubicin Mean Percentage Mean Absorbance Percentage of Survival
Concentration Absorbance of Survival
"B" MBCH "B" M8CH
(~M) (S.D. ) (S.D.) (S.O.) (s.O.)
40 0.025 13.46 0.028 0.040 15.09 18.51
(0.003) (1.36) (0.006) (0.002) (J .06) (0.69)
20 0.034 18.35 0.035 0.041 18.76 18.74
(0.002) (0.82) (0.001) (0.003) (0.70) (l.15)
10 o.on 17 .67 0.039 0.038 20.94 17.36
(0.003) (1.69) (0.003) (0.002) (1.63) (0.69)
5.0 0.075 40.78 0.076 0.063 41.46 28.85
(0.022) (12.15) (0.004) (0.011) (2.10) (4.97)
2.5 0.112 60.90 0.110 0.123 59.82 56.44
(0.027) (14.64) (0.022) (0 025) (11.70) (11. 36)
1.25 0.165 89.60 0.149 0.177 81.02 81. 38
(0.046) (25.10) (0.011) (0.005) (6.07) (2.31) ~
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Figure 28. Dose~Response curves for Cox and Cox C-13 hydrazone derivatives on
cell line OOL0320DM (mean ± S.D.).
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Table 12. Absorbance obtained from MTT assay following 24 hour exposure of L8174T cells
to Dox and Dox 3'-N-amide iamunoconjugates (standrad deviatioD, S.D.)
Doxorubicin conjugate Conjugate
DoxorUbicin Mean Percentage Mean Absorbance Percentage of Survival
Conc""l".tration Absorbance of Survival MBA MBCA MBUA MBA MBCA MBUA
(~M) (S.D.) (S.D.) (S.D. ) (S.D.)
0.037 5.75 0.621 0.472 --- 96.17 73.33
(0.004) (0.55) (0.067) (0.064) --- (10.30) (9.92)
5.0 0.023 3.57 0.584 0.603 0.619 90.33 93.59 77.50
(0.003) (0.49) (0.t')6~) (0.072) (0.115) (9.57) (11.20) (14.4])
2.5 0.041 6.41 0.631 0.506 0.717 97.72 78.61 89.74
(0.012) (1.89) (0.054) (0.039) (0.093) (8.29) (6.03) (11.62)
1.25 0.056 8.73 0.704 0.549 0.760 109.02 85.25 95.15
(0.011) (1.65) (0.060) (0.070) (0.095) (9.33) (10.92) (11.82)
0.625 0.2H 34.28 0.716 0.598 0.734 110.87 92.78
(0.050) (7.68) (0.058) (0.040) (0.060) (8.90) (6.18) (7.51)
* insufficient concentration in in vitro testing
~
~
Conjugales (Dox/MAb)
Dox
MAb-MBA-Dox (2.58)
MAb-MBCA-Dox (2.09)
MAb-MBUA-Dox (1.68)
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Figure 29. Dose-Response cw:ves for Dox and Dax 3 I -N-amide imnunoconjugates on
cell line LS174T (mean ± S.D.). ~~00
Table 13. Absorbance obtained froa KTT .ssay follovinq 24 hour uposu.r. ot L8174'r cells
to Dox: and Dox: C-13 hydrazone iaaunlJconjuqatas (standard Deviation, 8.0.)
Doxorubicin Doxorubicin Derivatives
Doxorubicin Hean Percentage Hean Absorbance Percentage of Survival
concentration Absorbance ot' Survival H8H MBCH H8H HBCH
CuM) (S.D.) (S.D.) (S.D.) (S.D.)
0.058 8.62 0.S17 0.428 52.48 46.00
(0.003) (0.49) (0.010) (0.030) (0.97) (3.17)
0.079 11.72 0.726 0.589 73.65 63.29
(0.010) (1.45) (0.090) (0.062) (9.09) (6.69)
2.0 0.120 17.84 0.682 0.696 69.18 74.87
(0.013) (1.90) (0.073) (0.039) (7.38) (4.18)
1.0 0.226 33.77 0.878 0.780 89.08 83. 85
(0. _:.13) (0.46) (0.086) (0.064) (8.68) (6.87)
0.5 0.350 52.28 0.915 0.852 92.91 91. 57
(0.022) (3.21) (0.083) (0.085) (8.39) (9.16)
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Table 14. A1::lsorbanc8 obtained from M'l'l assay following 24 bour exposure of COL0320DM
cells t.o Dox and Dox C-13 hydrazone iamunoconjugates IStandu-X'd Deviation, S.D.)
Doxorubicin Doxorubicin Derivatives
Doxorubici.. Mean Percentage Mean Absorbance Percentaqe of Survival
Concentration Absorbance of Survival MB" MBCH MB" MaCH
(p.M) (S.D.) (S.D.) (S.D. ) (S.D.)
B.O 0.040 13.91 0.170 0.270 99.40 102.77
(0.005) (1.84) (0.052) (0.057) (30.20) (21.67)
0.179
(0.017) (5.90) (0.04(;) (0.050) (26.81) (19.14)
2.0 0.138 48.n 0.163 0.309 95.03 117.69
(0.029) (10.16) (0.021) (0.037) (15.95) (13.99)
59.48 0.15.1 0.237 88.03 90.5.1
(0.033) (11.63) (0.030) (0.052) (17 .33) (19.96)
0.5 0.117 61.97 0.165 0.276 96.41 105.39
(0.021) (7.39) (0.025) (0.065) (14.58) (24.95)
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Figure 31. Dose-Response curves for Dcx and Dox. C-13 hydrazone :iIrmunoconjugates
on cell line <DL0320DM (mean ± S.D.).
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hydrazone derivatives showed similar cytotoxic effects when
compared to Dox on both l.S174T and C01.0320CM cell lines
(Figures 27 and 28). The lS174T cell line showed highet"
sensitivity to Dox and Dox hydrazone derivatives than the
COLQ320CM cell line.
Inmunoconjugates synthesized from Dox 3' ··N-amide
del~ivatives were not sufficiently cytotoxic to effect a 50%
inhibicion of growth of 18174'1' cell line (Figure 29). These
irrmunoconjugates exhibited no cytotoxicity even at 10 J1M.
However, the irrmunoconjugates prepared from Dox C-13 hydrazone
derivatives were sufficiently cytotoxic to achieve 50%
inhibition of LS174T cell growth at -8 1M (Figure 30) and had
no appreciable cytotoxic effects on the COL0320I:M cell line
(Figure 31).
III 3.5 50S-PAGE Analysis of Antibody and Irnmunoconjugates
The results of SOS-PAGE analysis of Dox 3' -N-amide and
Dox C-13 hydrazone inmunoconjugates are shown in E'igures 3?
and 33 respectively. In both figures, the parent 11-285~14 in
the gel (Lane 2) shows one rrajor band which corresponds to the
antilxxly rronomer at the position 150,000 KDa and one minor
band which presumably corresponds to an impurity. E'or the gel
with Dox 3' -N-amide inmunoconjugates Wigure 32), lanes 3 to
5 showing thiolated 11-285-14 with 7.14,6.55 and 6.26 SH/MAb
respectively contain at least two other minor bands of lower
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roolecular mass in CClfl'IParison to parent 11-285-14. These bands
may be antibody subunits. Lanes 7, 8 and 9, containing
irrrnunoconjugates 19, 20 and 21 respectively, show a series of
faint bands corresI;X)nding in positions to higher rrolecular
masses than antil::xxiy monomer. These bands indicate that
covalent cross-linking between antibody had occurred. For the
gel containing Dox C-13 hydrazone irrmmoconjugates (Figure
33), lanes 3 and 4 show thiolated 11-285-14 with 6.55 and 6.59
SH/MAb respectively; the faint bands at higher rrolecular mass
in cc:xr;>arsion to parent 11-285-14 (Lane 2) indicate that
covalent cross-linking between thiolated antiJ:xx:ly had occured.
The Dox~MBH and Dox-MBa-l immmoconjugates (22 and 23) on lanes
6 and 7 showed a similar pattern to thiolated antibody.
1B5
Lane
(KDa)
200--
116 __
97 --
66- •
43-- .,
Figure 32. SDS-PAGE of thiolated 11~285-14 and Dox 3'-N-
amide i.Jrmunoconjugates showing extra PAGE bands, and
control. parent 11·2&5·1.4. lanes are: lane 1, high
~;e~:~ ri{h~~tet~oi~~ii;_21~~42~o~~I~I~1;~~~:
~~;~a~fn;'f~~f;{e~:rc2tl~;2l~~~~ti~e~9,
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Figure 33. SDS-PAGE of thiolated 11-285-14 and Cox C-13
hydrazone itmtunoconjugates showing extra PAGE bands, and
control, parent 11-285-14. Lanes are: lane 1, high
molecular weight protein standard; lane 2, parent 11-285-
14; lanes 3 and 4, thiolated 11-285-14 containing 6.55 and
6.59 SH/antibody respectively; lanes 6 and 7, containing
illTlllUloconjugates 22 and 23 respectively.
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III 4.0 DISCUSSION
III 4.1 Introduction
Antilxxiy mediated targeting (AMTI is an attractive
approach in cnemotherapy. The selectivity of MAb to TM may
attain site-specific drug d~livery. However, the majoL"
problem in AMI' is how to produce drug-MAb conjugates by a
reliable method. The conventional methods using EDCI and
glutaraldehyde caused serious side reaction in
polymerization of antil:xx:1ies and dnlgs. Recently, efforts to
investigate the usefulness of PMr have led to the development
of a variety of methcds and reagents for protein-dnlg COVi:l.~ent
cross-linking. '!he use of heterobifWlctional cross-linking
reagents permits the conjugation reaction in a stepwise m:.mner
and permits the additional characterization of conjugate. 'lhe
principle aim of the studies in this thesis was to produt."t::
novel cross-linking reagents, to link. them to Doz, to
characterize them and then to undertake preliminary biologica I
evaluation of them.
Prior to assessing the efficacy of targeted cherrother.apy
using rronoclonal antilxldy drug il11'l'UJlOConjugates, it is
essential to evaluate the various comp....ments, target, carrier
and toxic agent, of the targeting system, An advantage in the
use of dnlgs as cytotoxic agents is that considerable
inforrration has been gained on their use in th~ treat1l'.ent of
Dox is one of the roost comronly used a..,t:icancer
188
agents in chemotherapy. It is effective for a wide range of
cancer, but its use is limited by non-specific toxicity to
normal tissues. Thus, Dox is very useful as a toxic agent for
AI-1T. The characterisation of the target, human turror cell
lines expressing the tumor associated antigen CEA., and the
carrier, the monoclonal anti-CEA. antibody 11-285-14, were well
established in the Oncology Research Laboratory. The
potential of targeted cherrotherapy using vindesine 11-285-14
conjugates had previously been deooostrated in vi tro and in
vivo (Casson et aI, 1987; Ford et aI, 19B7b). Preliminary
.results with Dox-1l-285-14 conjugates had also shown efficacy
in vitro (Richardson et aI, 1989). Thus, carrying this work
a step further, we investigated the efficacy of 00;,-11-285-14
conjugates using novel heterobifWlctional spacers.
IV 4.2 pH Optimization of MaleiJnide Reactions
The heterobifWlctional cross-linking reagents containing
maleimide are widely used in mug-protein conjugation. The
coupling condition of thiol to male imide is pH dependent. At
higher pH, the deprotonated thiol is a strong nucleophilic
species for Michael addition to the double bond of maleimide.
However, maleimide is susceptible to base-catalyzed. hydrolysis
in aqueous solution and the product maleamic acid will not
react with the cysteine thiol (Gregory, 1955). To understand
the extent of the conjugation of MAb to maleimido doxorubicin
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derivatives, we characterized the stability and reactivity of
the spacers (3, 4 and 5) at several pHs using a
spectrophotometric method. These experimental results may be
useful to optimize the conjugation reaction between drug and
antilxxiy.
The spacers (3, 4 and 5) absorb ultraviolet light in a
spectrum characteristic of phenylmaleimide chromophore. Their
absorbance maxima are 246 - 249 run. When maleimides were
added to an excess of cysteine at pH 7.0 and 6.5, coupling
occured cleanly with the smooth conversion of the IMjOl-
phenylmaleimide absorption into a new chronnphore centered at
262 - 266 run (Figures la, 13 and 16). As expected in a
reaction in which the deprotonated thicl is a strong
nucleophilic species, the rate of coupling, cysteine-to-spacer
condenf'lation, was slower at pH 6.5 and more rapid at pH 7.0
(Table 2, 3 and 4, and Figure 12A, 15A and 18A). At pH 7.0,
rrore deprotonated thiols exist for Michael addition. Neither
MBA. nor MBllA showed the same chromophoric change at pH 7.0 and
6.5 within a 1.5 h incubation time. It may suggest that leAs
maleimide reacts with cysteine thiol at pH 6.5.
We next investigated the rate of hydrolysis of the
spacers at several pH values. The spectra, Figure 11, 11 and
17, clearly indicate the chromophore of the newly formed
maleamic acid, 284 - 286 run, during hydrolysis at different
pHs and the results are sUTITllT'arized in Tables 2, 3 and 4 I and
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Pigures 128, 158 and 18B. At ph 6.5 an aqueous solution of
maleimide did not show appreciablti! absorption in the range 270
- 310 run and no absorbance developed within 1.5h incubation
time. The maleimide was stable at pH 6.5. However, after
incubation at pH 8.0, strong absorbance :i.n the region 270 -
310 nm was obtained. The chromophoric change was rapid at pH
8.0 and slower at pH 7.0 (Figures 128, 158 and 18B). These
observations suggested that alkaline hydrolysis of maleimide
was rapid at: pH 8.0 and slow at pH 7.0.
The conjugation reaction between the maleimide of Dcx
derivatives and the thi01 groups of MAb proceeds rrore slowly
than the model reaction of the spacers and cysteine because of
the steric hindrance to reaction, local ionization in protein
or dilution factor. 'Ihe rate of hydrolysis of maleimide can
limit the extent of conjugation of MAb to IfIa]~imido-Dox
derivatives and pH 6.5 will be the ideal conjugation
condition. However, based on the experimental results, less
conjugation occured in MBA and MBUA when the chromophoric
changes are compared (Figures l2A and l8A). After a certain
degree of thio1.ation of MAb optimal conjugation IT\3.y not be
a' tained at pH 6.5. Thus, pH 7.0 was chosen to be the optimal
condition for the maleimide-thiol coupling reaction.
III 4.3 Thiolation or 11-285-14
Chemical cross -linking of biological components such as
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drug-protein conjugation usually involves chemical
modification of proteins. Chemical conjugation of proteins to
drugs depend on the reactivities of the constituents of
proteins and the specificities of the cross-linking reagents.
Amino groups of lysines are S'",nerally the most abundant
functional groups on the surface of protein molecules that are
susceptible for' conversion to other functionalities. The
conversion of amino to sulfhydryl groups becomes the most
attractive approach for conjugation and the most potent
nucleophile, thiol, increase the reactivity of protein for
conjugation. Several reagents have been employed to introduce
thiol groups into proteins and 2 - iminothiolane (2 - IT) is the
rost cormonly used one. It is quite water soluble and reacts
rapidly with amino groups at pH 7.0 or above. After' the
addition of thiol rooieties, the cationic charges of the
modified amino groups can be preserved. Moreover, the thiols
show high reactivity to various maleimidyl g,;:oups.
11-285-14 was subjected to different degrees of
thiolation with different arrounts of 2-IT (Figure 20). 'l'he
number of thiol groups was determined by D'I'NB at pH 7.1'.7.
DTNB is not a stable reagent. Dissolved in phosphate buffer
(pH 7.0) and kept in the dark at -20"'C, this is sLable
indefinitely. The number of t:hiol groups incorporated into
the Will is highly correlated to the amount of 2-IT used (R-sq
'" 99.68%, P < 0.0001) (Figure 20). The thiolated MAbs were
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separated on a Sephadex G-25 column rather than dialysis
because serious protein precipitation occured during dialysis.
The generation of reactive chiol groups on the MAb is
easily controlled by using 2-IT, but the addition of chiols is
a random process. There is no preferred group or subset of
lysines that rE:::act faster than the others with 2-IT (Figure
20). There may be a wide spread of individual MAb lTK)lecules
containing chiol groups higher and lower than the average.
The binding activity of thiolated 11-285-14 to CFA may not be
uniform from molecule to molecule.
Before using the thiolated 11-285-14 for conjugation
reactions, binding studies were performed to confirm the
binding of antib::xiy to CEA by ELISA. The binding activity of
11-285-14 decreases as the number of chiol groups on antil::xxly
increases (Figure 21), presurrably because of the thiolation on
the active-site lysines. PAGE (Figures 32 ~ 33) showed the
major bands of MAb at MW 150,000 from non-thiolated 11-285-14
and thiolated 11-285~14. 'l1le parent 11-285-14 used had been
partly purified by protein A affinity chromatography.
However, one contaminant around 190,000 was observed. From
lane 3 - 5 in figure 32, the absence of clear bands higher
than 150,000 (other than the 190,000 band) indicates that
there is no covalent cross-linking between antibody. The
extra bands at MW lower than 150, 000 may be due to the
breakdown of antibody and they are not in the parent antibody
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(Lane 2). In figure 33, the faint bands at molecular weight
higher than 150, 000 in lanes 3 and 4 indicate the covalent
cross-linking between thiolated antibody. However, use of 2-
IT is a quite reliable method for thiolation without serious
protein-protein cross-linking before protein-drug conjugation.
Probably, serious cross-linking between antibodies does not
occur because of low protein concentration (1.48 - 1. 70 fig/mIl
and low chi01 substitution (6.26 - 7.14 SH/MAb) in our
experiments.
III 4.4 Production of Drug Monoclonal Antibody Conjugates
Dox-1l-285-14 conjugate showed an unresolved spectnml
()..""" 487 run) relative to Dox derivatives (Figure 34). It may
be the hypochroism (e - BOOO M'l em'l) which is charactp.ristic
of stacking aggregation of the anthracycl ine chromophore
(Menozzi et al, 1984), The unresolved spectrum may be due the
microenvironment of antil::x:xiy which affects the chrom:>phore of
Dox conjugated to antiOOdy. The oolar extinction coefficient
used in our experiment to estimate the drug botmd to antibody
is between 12380 and 13236 M- I cm"l (Table 5). The drug to
protein ratio may be underestimated with these values.
The conjugation of drugs to antibodies is chemically
difficult, especially fer the highly hydrophobic drugs
conjugated to hydrophilic antibodies. A number of methods
have been extensively revietoJed and result in 4 - 10 molecules
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Figure 34. Light absorption spectra of
MBA-Dox derivative (---) and MBA-Dox
conjugate (-)
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of drug per molecule of antibody (Pietersz, 1990). During the
conjugation reaction, there is loss of antibody activity, up
to IO-fold loss of drug activity and an inevitable protein
precipitation. Antibody-daunorubicin conjugates prepared with
succinyl linkages were prone to aggregation at 3 - 4 molecules
of drug per TOOlecule of antil::::ody (Al:::oud et a1. 1989). The
conjugates prepared from IgG and Dox derivatives containing a
reactive N-hydroxysllccinimide ester moiety (Dox-DSP) showed an
extensive protein precipitation with average of
substitution of 1 to 2 Dox molecules per molecule of I9G
(Demant, Jensen & Sehested, 1991).
The incorporation of spacer moieties may improve the
coupling efficiency. The longer spacer arm should have
increased the efficiency of the coupling reaction. At the
beginning of the synthesis of our irrmunoconjugates. the
problem of protein precipitation was very serious even in the
presence of a lO-fold excess of drug. The gel: filtration
colullU1 retained TT"Ost of the protein. After the improvement of
the method, the drug was added in aliquots instead of one
batch. All conjugation solutions were turbid and only Dox-MBA
and Dox-MBCA. conjugates appeared to have no aggregation during
the conjugation reaction. 'Ihe control containing Day.
derivatives with non-thiolated antil:xxUes or Doy. with
thiolatea. antibody remained as clear reddish solutions without
any sign of protein precipitation. Only Doy.-MBUA showed very
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high non-covalent binding to non-thiolated 11-285-1<\, giving
a conjugate containing 3.60 mlecuies of drug per rrolecule of
antibody and high protein recovery. It is clear that the
behavior of thiolated antil::xxly or non-thiolated antibody with
Dox-maleimido derivatives is different.
Hydrophobic protein-drug interactions and protein
structure may affect the properties of the conjugation
products and be responsible for the protein aggregation.
Demant et al. (1991) suggest that protein-anthracycline
complex fonnation is cooperative and involves two steps:
initial self-association of anthracycline into aggregated
structures, subsequent binding of protein at the aggregate
surface and the forrt'ation of a structural resemblance to
lipoproteins with a hydrophobic core stabilized by hydrophilic
coat. It is possible that Dox-maleimido derivatives tend to
form lipoprotein like structures and becorr.e precipitated in
aqueous solutions. Willner et al. (1993) suggest that the
tendency of protein precipitation during conjugation resides
in the antibody and not the linkers because it persists with
thiolation by either N-succinimidyl-3-(2-
pyridinyldithiolpropionate (SPDP) or 2-IT. Protein yields of
50 - 80% and 20 - 50% were obtained for SPDP-thiolated and 2-
IT-thiolated MAbs respectively (Greenfield et al, 1990).
Thus, the loss of positive charge when lysine amino groups
react with SPDP but not with 2-IT is not responsible for the
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protein precipitation. !he problem of precipitation can be
overcome when thiolation of lysines is abandoned. The
dithiothreitol (D'IT) reduction of MAb may be a rrore promising
method (Willner et aI, 1993). Final protein yields of 32
60\ were obtained in our conjugation reactions (Table 7) .
yield as high as 60% is reasonable in comparsion to the yields
obtained by other investigators. The loss of protein may in
part be due to the Amicon filters used for ultrafiltration and
Millex GV filters used for sterilization. These filters
retained some of the conjugates.
SDS-PAGE analysis of Dox-1l-285-14 conjugates (19, 20,
21, 22 and 23) showed extra bands of 1lO1ecular weight (MW)
higher than 150,000 (MW of ll'Ouse IgGl)' It suggests that
covalent cross-linking between irrmunoconjugates occured. All
illlllUnoconjugates, except Dox-MBUA conjugate, showed a most
intensely stained band at MW 150,000, indicating that most of
the irnnunoconjugate rerrained as a monomer.
III 4.5 In Vitro Efficacy
All Dox 3' -N-amide derivatives were less toxic than the
unconjugated drug against the L"EA IXlsitive cell line, LS174T;
Dox-MBUA derivatives failed to reach 50% inhibition of cell
growth at 40 1Jl" concentration. However, the cytOi:oxicity of
the Dox C-13 hydrazone derivatives was of similar potency to
Dox on both the CEA IXlsitive cell line, LS174T, and the CF..A
19B
negative cell line, COW320DM; LS174T is more sensitive to Dox
in comparsion to COW320I:M. The binding of Dox to DNA by
intercalation is one of the mst acceptable theories for its
cytotoxicity. Structure-activity studies with anthracyclines
have shown that the sugar residue is an important contril;;utor
to cytotoxicity. Dox analogues bearing N-acyl substituents
are less potent than those bearing a free amino group
(Yamarroto, Acton & Henry, 1972; Gabbay et aI, 1976). However,
recent X-ray crystallographic studies of anthracycline-
oligodeoxynucleotide complexes indicates that the amino group
does not interact with DNA (Frederick & Wang et aI, 1990).
It has been suggested that anthracycline irrmunoconjugates
do not show significant cytotoxicity if the drugs are not
cteconjugated from antibody at target site (Hermentin & Seiler,
1988). The attachment of Dox to antibody with acid-sensitive
spacers and the release of Dox from ilTlTlUnoconjugates after
internalization inside the lysosome compal"tment enable the
drug to retain pharmacological activity. TIle tritylated 3 I -N-
[p-aminobenzoyl]-·amide-daunorubicin was unstable in acetic
acid and detritylation at pH 4 caused the release of
daunorubicin. According to these authors, the aromatic ring
prorootes the hydrolysis of the 3 I -N-amide linkage (Rosik &
Sweet, 1990). Previous work in this laboratory has shown that
the anti-CEA rronoclonal antilxxly 11-285-14 is internalized by
LS174T cells, but is not internalized by COL0320DM (Tsaltas,
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Ford & Gallant, 1992). The internalization favors acidic
cleavage of the drug from the itmnJnoconjugate if, of course,
it is hydrolysable. However I with a similar cornpotrnd, Dox-MBI\
derivative and irmnmoconjugate, did not show any in vi tn>
activity. This Tray be due to rraleimide preventing the
hydrolysis of aromatic amide bonding between MBA. and Dox. The
Dox(hydrazone-linked) irrmunoconjugates were more potent than
Dox 3' -N-amide irrmunoconjugates but not as pot.ent as their
starting material, Dox C-13 hydrazone derivatives.
The results from ELISA showed the retention of bindinl
activity of inmunoconjugates (Figures 24 and 25). Because of
the low mug to protein ratios (1.68 - 2.58 molecule of
drug/roolecule of MAb), all preparations will contain 000-
conjugated antilxxiy. Inevitably, it is anticipated that the
non-conjugated antibody will he responsible Eor some of the
reactivity of irmnmoconjugates in ELISA. 'Thus, it is hard to
prove the selectivity and binding activity of these
irrrnunoconjugates. However, it is quite clear that within MAb~
MBA-Dox and MAb-MBCA-Dox conjugates there were little or no
ro1Ab inactivation whereas with the MAb-MBUA-Doy., MAb-MBH-Do7.
and MAb~MBQI-Dox conjugates there were a reducti.on in CEA
binding. Although the binding activity has been apparently
retained, the ve1.7 poor cytotoxicity of Dox )' -N-amide
inrnunoconjugates is probably due to a reduced intracellular.
release of the active drug from the conjugates.
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Because of the difficulty and serious protein
precipitation during conjugation reaction in high drug
substitution, Dox-1l-28S-14 conjugate preparations were
obtained in low drug substitution. As a result, insufficient
drug substitution did not permit significant cytotoxic effects
to be observed ;ond prevented a conclusion being reached on the
efficacy of the invrnmoconjugates compared to the lll1conjugated
Dox. The final purified and concentrated preparations only
permitted cytotoxicity testing over a limited range. However,
if thp. drug substitution of Dox )'-N-amide
illl\1JJloconjugates i.ncreased, anticipate that
cytotoxicit}· would probably still be nxxlest.
In vitro testing results from Dox )'-N-amide derivatives
and irnnunoconjugates were matched with each other; no activity
was obtained from any drug derivative and its conjugate. If
the cb:ug derivatives do not exhibit any cytotoxicity, one
might expect that the inmmoconjuagtes should not show any
activity when tested in vitro. However, there have been a few
reports in the literature where drug derivatives have been
inactive in vitro but after linkage to antibody they have
shown increased cytotoxicity of the inm..moconjugates compared
to unconjugated drug (Gat:nett et at. 1986, Smyth et at. 1986)
and this is why we proceeded with the production of
inrnunoconjugates. Also, a recent report by Henn et al 1993
indicated that, in general, 5-fluro-2' -deoxyuridine
derivatives had no activity in - vitro" HOWeVeL",
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irrmunoconjugate was non-specifically cytotoxic to both antigen
positive and negative cells. These observations therefore
cannot be explained by the ir..:::reased uptake of the
irrmunoconjugates by the target cells and suggest that the
conjugation procedure has resulted in loss of selectivil:y of
the carrier antibody. This is not the same as the resultu we
obtained with the Dox 3' -N-amide irrmunoconjugates where there
was no activity with antigen positive cells.
The cytotoxicity of the Dox(hydrazone-linkedl
inmmoconjugates was less than the coressponding Dox hydrazone
derivatives wt showed significant specificity after"
conjugation of antibody. The dose-response curves show a
gradual reduction in the percentage of surviving cells as the
irrmunoconjugate concentration increases when the high eel\.
expression cell line, LS174T, is evaluated (Figure 30).
Selectivity is confirmed by the absence of conjugate effect on
the low CEA expressing cell line, C01.D320D1, with the same
concentration range (Figure )1). Although the Do:-: (hydrazone-
linked) ilmlUI1OConjugates show efficacy in in vitro testirB,
these irmmnoconjugates were just sufficiently cytotoxic to
achieve 50% inhibition of 1.S174T at B pM. The effie'lcy of
irrmunoconjugates depends on the density of antigen ezpressed
on the target cells and the quantity of dIug delivered per.
antibody rroleeule. Thus, irranunoconjugates prepared with i)
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higher drug substitution should be more potent than low drug
substitution because more drug is delivered per antibJdy
molecule round to target cell. Because of the protein
aggregation and preciptation, drug substitutions, 2.24 - 2.27,
obtained in Dox(hydrazone-linkedl irrmunoconjugates is probably
too low for good antiturror activity. These assays require
considerably higher drug concentration or higher Chug
substi tution which were not possible here because of the
protein precip\ 3.tion.
The use of heterobifunctional spacers with hydrazide and
J1laleimide to cross-link Dox and antibody will be the current
approach to prepare Dox irrmunoconjugate for antibody mediated
targeting. Irmumoconjugates (BR96-Doxl prepared from
conjugating BR96 to (6-maleimidocaproyl) hydrazone of Dox were
evaluated in in V.l tra and in human xenograft models (Trail et
aI, 1993; Willner et aI, 1993). Treatment of established
human turrors in athymic rata with BR96-Dox conjugates produced
complete turror regressions and long term cures. BR96 is a
chimeric (rrouse-human) MAb which binds to a TM that is
closely related to Lewis Y (leY) expressed on the surface of
human carcinoma cells of the breast, colon, lung, and ovary.
However, LeY also exits in a wide range of normal cells such
as blood cells. The first criterion of AMI' is antigen
specificity in whlch the antigens must be strongly expressed
in turrors, allowing the conjugates to target the antigen-
203
positive turror cells and sparing antigen-negative normal
cells. CEA is strongly expressed by rost carcinanas of the
colon, stomach and breast. Moreover. ('FA is present in wch
smaller arromts on normal tissues and is relatively specific
for tUTOr. Thus. Dox-anti-CE'A conjugate is a tOOre suitable
nodel for detailed studies in /lMr. In the future. treatment
of human cancer with ilTlTlllIlOConjugates may provide the
additional therapeutic option hoped for.
20'
III 5.0 IMMUNOCHEM:J'I'HERAPY: PROSPECTS AND FUTURE STUDIES
The ultirrate aim of any new therapeutic approach is to
apply it in the clinic. The discovery of hybridoma technology
opened the new generat.ion of irrmunocherootherapy using
Ironoclonal antibodies as carriers of therapeutic agents.
Before proceeding through Phase I, II and III Clinical Trials,
it is important to characterize the irrmmoconjugates and then
assess their efficacy and toxicity using a relevant pre-
clinical model.
The use of CEA as a target has potential clinical
applications in both diagnosis and therapy. 'The broad
clinical evaluation and the well-characterized response and
toxicity profiles of chemotherapeutic agents make them
attractive for linkage to antibodies. Drug irrmunoconjugates
have been shown to retain both in vi tro and in vivo
cytotoxicity in many investigations.
Several fundamental questions are outstanding and
extensive investigation is required before the initiation of
clinical trials. The TrOst COTlm:m problem is the difficulty in
effectively binding chemotherapeutic agents to antiOOdies.
The improvement of conjugation procedures is esential to
optimize the yield of il1VltUIloconjugates. The determination of
the nature, covalent or non-covalent, and the chemical
properties, releasable or non-releasable, of the linkage
between the drug and antibody provide the information about
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the stability of ilt1lUllOCOl1jugates. The fate of the conjugate
following systemic administration is unclear.
'Ihe work presented in this thesis provide sc:me valuable
information for future studies: 1) the synthesis of
heterobifunctional spacers is well characterized: 2) the
production of ilTl11..lnOConjugates can be performed in a stepwise
manner, permitting additional characterization; 3)
i\1'lTlUIloconjugates prepared from Dox 3' -N-amide derivatives are
not active in in vitro testing: and 4) Dox(hydrazone~1inked)
inm..moconjugates are active in in vitro and appear to provide
a more promising approach.
Further investigation of the correct spacer groups for
effective release of drug and the understanding of the ey.act
mechanism of release of the drug at target site appear to be
essential for develc:pre:nt of doxorubicin conjugates. The
ifYl)rovement of conjugation :::ondition and purification of
il11T1lIloconjugate are essential to prevent protein aggregation
and precipitation. '!hese will hopefully contribute to the
development of better conjugates for antilxldy Trediated
targeting .
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